

# **Amelioration of non-alcoholic fatty liver disease by targeting G protein-coupled receptor**

## **110: A preclinical study**

Mengyao Wu <sup>1</sup>, Tak-Ho Lo <sup>1</sup>, Liping Li <sup>2</sup>, Jia Sun <sup>2</sup>, Chujun Deng <sup>1</sup>, Ka-Ying Chan <sup>1</sup>, Xiang Li <sup>1</sup>, Steve Ting-Yuan Yeh <sup>3</sup>, Jimmy Tsz Hang Lee <sup>4,5</sup>, Pauline Po Yee Lui <sup>6</sup>, Aimin Xu<sup>4,5</sup>, Chi-Ming Wong <sup>1,5,7</sup> \*

<sup>1</sup> Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong SAR, China

<sup>2</sup> Zhujiang Hospital, Southern Medical University, China

<sup>3</sup> Ionis Pharmaceuticals, USA

<sup>4</sup> Department of Medicine, The University of Hong Kong, Hong Kong SAR, China.

<sup>5</sup> The State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong SAR, China

<sup>6</sup> Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Hong Kong SAR, China

<sup>7</sup> Hong Kong Polytechnic University Shenzhen Research Institute, China

\* Correspondence: [chi-ming.cm.wong@polyu.edu.hk](mailto:chi-ming.cm.wong@polyu.edu.hk); Tel.: 852-34008564

## **Competing Interests**

None.

## **Highlights**

- GPR110 regulates hepatic lipid metabolism.
- High level of hepatic GPR110 aggravates the progression of NAFLD by inducing SCD1 expression.
- Reduction in hepatic GPR110 is required to alleviate the progression of NAFLD.
- Targeting hepatic GPR110 improves hepatic steatosis.

## Abstract

**Background:** Recent research has shown that the G protein-coupled receptor 110 (GPR110) is an oncogene. The evidence mainly based on high expression of GPR110 in numerous cancer types; and knockdown GPR110 can reduced the cell migration, invasion, and proliferation. GPR110 is, however, mostly expressed in the liver of healthy individuals. The function of GPR110 in liver has not been revealed. Interestingly, expression level of hepatic GPR110 is dramatically decreased in obese subjects. Here, we examined whether GPR110 has a role in liver metabolism.

**Methods:** We used recombinant adeno-associated virus-mediated gene delivery system and antisense oligonucleotide to manipulate the hepatic GPR110 expression level in diet-induced obese mice to investigate the role of GPR110 in hepatic steatosis. The clinical relevance was examined using transcriptome profiling and archived biopsy specimens of liver tissues from non-alcoholic fatty liver disease (NAFLD) patients with different degree of fatty liver.

**Results:** The expression of GPR110 in the liver was directly correlated to fat content in the livers of both obese mice and NAFLD patients. Stearoyl-coA desaturase 1 (SCD1), a crucial enzyme in hepatic de novo lipogenesis, was identified as a downstream target of GPR110 by RNA-sequencing analysis. Treatment with the liver-specific SCD1 inhibitor MK8245 and specific shRNAs against SCD1 in primary hepatocytes improved the hepatic steatosis of GPR110-overexpressing mice and lipid profile of hepatocytes, respectively.

**Conclusions:** These results indicate GPR110 regulates hepatic lipid metabolism through controlling the expression of SCD1. Down-regulation of GPR110 expression can potentially serve as a protective mechanism to stop the over-accumulation of fat in the liver in obese subjects. Overall, our findings not only reveal a new mechanism regulation the progression of NALFD, but also proposed a novel therapeutic approach to combat NAFLD by targeting GPR110.

**Fundings:** This work was supported in part by National Natural Science Foundation of China 81870586 (CMW), 82270941 and 81974117 (JS), Area of Excellence AoE/M-707/18 (AX and CMW), and General Research Fund 15101520 (CMW).

**Keywords:**

GPR110, SCD1, obesity, hepatic steatosis, non-alcoholic fatty liver disease (NAFLD)

**Abbreviations:**

ADGRE1, adhesion G Protein-Coupled Receptor E1; ADV, adenovirus; ALT, alanine aminotransferase; ASO, antisense oligonucleotide; AST, aspartate aminotransferase; cDNA, complementary DNA; CHO, cholesterol; DIO, diet-induced obesity; FGF21, fibroblast growth factor 21; GPCR, G protein coupled receptor; GPR110, G-protein coupled receptor 110; EWAT, epididymal white tissue; FFA, free fatty acids; GFP, green fluorescent protein; HCC, hepatocellular carcinoma; HDL, high-density lipoprotein; H&E, hematoxylin and eosin; HFD, high-fat diet; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance; KEGG, Kyoto Encyclopedia of Genes and Genomes; LDL, low-density lipoprotein; MUFA, monounsaturated fatty acids; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NCD, non-communicable diseases; NPC, Non-parenchymal cells; ORO, Oil Red O; SCD1, stearoyl-CoA desaturase-1; rAAV, recombinant adeno-associated virus; STC, standard chow diet; TG triglyceride.

## 1. Introduction

Liver is a vital organ as it is the site for undergoing a number of crucial physiological processes including digestion, metabolism, immunity and storage of nutrients [1]. Over-storage of lipid in the hepatocytes not caused by alcohol is known as non-alcoholic fatty liver disease (NAFLD), which is the most common liver pathological condition with a worldwide prevalence of 25% [2]. The development of NAFLD is contributed by many factors such as lipid metabolism disorders, over- or mal-nutrition, inflammation, virus infection, or liver injuries [3]. NAFLD usually does not entail any symptoms at early stages. However, if left untreated, NAFLD accounts for approximately 85% of all chronic noncommunicable diseases (NCDs), such as type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD) and chronic kidney disease (CKD) [4, 5]. In addition, NAFLD may progress to non-alcoholic steatohepatitis (NASH) with fibrosis, cirrhosis or even hepatocellular carcinoma (HCC) [6]. Therefore, NAFLD imposes high economic and social burdens in terms of work productivity, health-related life quality and use of healthcare resources [5].

Improvement in managing NAFLD helps to resolve at least partially the progression of these diseases. Stopping the progression of NAFLD by lifestyle modifications such as increasing physical exercise activity and reduction of hypercaloric diet are only effective during the early stages before there is fibrosis. No medication is available to reverse the excessive fat storage in the liver once NASH developed. Therefore, it is urgently needed to unravel the mechanisms of NAFLD in order to accelerate the development, implementation, and explore new targets for the development of diagnostic tests and cost-effective therapies.

G protein-coupled receptors (GPCRs) are the largest and most diverse family of membrane receptor that play important roles in regulating most cellular and physiological processes [7]. GPCRs are major targets for currently approved drugs [8, 9]. A few GPCRs have been shown to play key roles in NAFLD and modulating their activities to ameliorate liver-related metabolic syndrome was proposed as NAFLD treatment [10, 11]. However, currently proposed targets for GPCR-medicated NAFLD treatment are not exclusively expressed in hepatocytes, thus the potential side effects on other organs should be considered.

Human GPR110 was identified by phylogenetic analysis based on highly conserved amino acid sequences of the G protein coupled receptor transmembrane domains in 2002 [12]. Mouse ortholog of hGPR110 was identified by the same research team two years later [13] and various splice variants were detected in deep sequencing experiments [14, 15]. So far, most GPR110 related studies focused on its tumorigenicity. In general, overexpression of GPR110 was observed in various cancers, and it was required to promote cancer cell survival, proliferation, and migration [16-21]. Therefore, it was suggested that targeting GPR110 may represent a new therapeutic strategy for anti-cancer treatment. It was also reported that GPR110 is required for proper fetal brain development and amelioration of neuroinflammation [22]. However, GPR110 is predominantly expressed in health adult livers. The function of hepatic GPR110 remains unexplored.

In this study, we provide the first evidence that GPR110 induces the expression of SCD1, which contributes to NAFLD. By HFD-induced NAFLD mouse model [23], we also show that the repression of hepatic GPR110 expression is a potential protective mechanism of preventing over accumulation of lipid in liver. Importantly, our findings not only reveal a new mechanism regulation the progression of NAFLD, but also proposed a novel therapeutic approach to combat NAFLD by targeting GPR110.

## 2. Methods

### 2.1. Animals

All animal procedures were approved by the Animal Subjects Ethics Sub-Committee of the Hong Kong Polytechnic University and were conducted in accordance with the guidelines of the Centralized Animals Facilities. In general, eight-week-old C57BL/6J male mice were housed in pathogen-free conditions at controlled temperature with a 12-hour light-dark cycle and access to food and water *ad libitum*. The eight-week-old male mice were divided into two groups and fed with either standard chow diet (STC, 18.3% protein, 10.2% fat, 71.5% carbohydrates, Research Diet Inc., New Brunswick, NJ, USA) or high-fat diet (HFD, 20% protein, 45% fat, 35% carbohydrates, Research Diets Inc., New Brunswick, NJ, USA) for 8 weeks. The sample size was calculated based on previous findings, suggesting that group sizes of  $n=7-8$  would be sufficient [24].

The recombinant adeno-associated virus vector rAAV2/8 transduction was conducted as described previously [25, 26]. Briefly, mice were tail vein injected with  $3 \times 10^{11}$  rAAV2/8 vector harboring either green fluorescent protein (GFP) or GPR110. For antisense oligonucleotide (ASO) delivery, validated ASOs against mouse GPR110 were provided by Ionis Pharmaceuticals and injected subcutaneously once a week at 5 mg/kg body weight to the mice. For SCD1 inhibitor delivery, MK-8245 (MedChemExpress, NJ, USA) was gavaged at 10 mg/kg BW once a week [27]. All measurements were carried out in a randomized order.

### 2.2. Primary hepatocyte isolation and adenovirus infection

Primary hepatocytes from different groups of mice were isolated using a two-step perfusion method as previously described [28, 29]. Briefly, type II collagenase was perfused to mice at a flow rate of 10 ml/min. Liver was collected and mesh in serum-free DMEM and hepatocytes were pelleted by centrifugation. For the supernatant containing nonparenchymal cells (NPCs), gradient solutions of Percoll were used for extraction. For adenovirus viral infection experiments, serum-starved cells were

infected with adenoviruses carrying mouse GPR110 cDNA to overexpress GPR110. Similar adenoviral vectors encoding the green fluorescent protein (GFP) gene were used as controls.

### 2.3. Cell culture and Luciferase Reporter Assay

HEK293 cells were cultured in DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37 °C and 5% CO<sub>2</sub>. HEK293 cells were seeded in 6-well plates and were transfected with pGL3-SCD1 promoter and adenoviral vector expressing either GPR110 (ADV-GPR110) or GFP (ADV-GFP) by using the transfection reagent (#E4981, Promega, WI, USA), following the manufacturer's instruction. DHEA (C3270, APExBIO, TX, USA) was added into cells at the concentration of 100 µM and incubated at 37 °C for 24h. For the luciferase reporter assay, pRL-TK (Renilla luciferase) reporter plasmid was used as a transfection control. The luciferase assays were performed by using the Dual-Luciferase Reporter Assay System (#E1960, Promega, WI, USA).

### 2.4. Biochemical analysis

For glucose profile measurement, the blood glucose and insulin level were measured by collecting the blood samples from the tip of the tail using Accu-Chek® glucometer (Roche Diagnostics, Indiana, USA) as described [30]. For the glucose tolerance test (GTT), insulin tolerance test (ITT) and pyruvate tolerance test (PTT), mice were fasted overnight prior to intraperitoneal injection of glucose (1 g/kg body weight (BW) (Sigma, St. Louis, MO), 0.75 U/kg BW insulin (Novolin R, Novo Nordisk, Bagsvaerd, Denmark) or 1 g/kg BW pyruvate (Sigma, St. Louis, MO). Blood glucose levels were measured from the tip of tail vein at 15, 30, 60, 90 and 120 minutes after injection. For plasma and hepatic lipid level, serum levels of triglyceride (TG) and total cholesterol (CHO) were measured using commercial kit (Biosino, biotechnology and science INC, China) according to the manufacturer's instructions. Hepatic lipids were extracted using Folch methodology and liver extract was dissolved in ethanol for TG and CHO measurement. Both serum and hepatic levels of free fatty acid (FFA) were measured using commercial kit (Solarbio, China) according to the manufacturer's instructions. For liver function assay,

the alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were measured in serum using commercial kits (Stanbio, USA) according to the manufacturer's instructions.

## 2.5. Histopathologic and Western blot analysis

Hematoxylin and eosin (H&E) and Oil Red O (ORO) staining were performed on paraffin-embedded and frozen liver sections, respectively. Detailed procedures of H&E and ORO were described previously [31, 32]. Representative histopathological images were acquired with a light microscope (Olympus, Tokyo, Japan). Western blot analysis was performed as previously described [25, 26, 28, 29]. Briefly, total protein was extracted from tissues and cultured cells with RIPA lysis buffer (65 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS). Protein samples were then separated by gel electrophoresis and then transferred to PVDF membranes (IPVH00010, Merck Millipore, CA, USA). The expression of protein was detected by a ChemiDoc MP Imaging System (bio-Rad, Hercules, CA, USA). Primary antibodies used were shown in Table S1.

**Table S1.** List of primary antibodies

Antibody name	Catalog number	Manufacturer	Dilution
Rabbit anti-GPR110	orb157302	Biorbyt	1:1000
Rabbit anti-SCD1	ab236868,	Abcam	1:1000
Mouse anti-GAPDH	40004-I-Ig	Proteintech	1:1000
Rabbit anti-CD11b	ab133357	Abcam	1:1000
Rabbit anti-albumin	ab207327	Abcam	1:1000
Mouse anti-beta tubulin	66246-I-Ig	Proteintech	1:1000
Mouse anti-beta actin	60008-I-Ig	Proteintech	1:1000
Mouse anti-flag tag	66008-2-Ig	Proteintech	1:1000

## 2.6. Quantitative real time PCR analysis

Total RNA was extracted with RNAiso Plus (#9109, TakaRa Bio Inc., Shiga, Japan) as previously described. RNA was reverse transcribed into cDNA with PrimeScript™ RT reagent Kit (#RR037, TakaRa Bio Inc., Shiga, Japan). cDNA was then amplified with TB green Premix Ex Taq™ II (Til Rnase H Plus) (##RR820A, TakaRa Bio Inc., Shiga, Japan). The real-time PCR was conducted with a LightCycler 96 qPCR System (Roche, Basel, Switzerland). The relative quantity of the targeted RNA



was calculated through normalization to the quantity of the corresponding GAPDH mRNA level.

Detailed primer sequences were listed below in Table S2.

**Table S2.** List of primers used for qPCR

Gene name	Primer sequences (5'-3')	
	Forward	Reverse
GPR110	CCAAGAGAAGCCAAACCTCC	TTCGATAAGCCAGCAGGATG
SCD1	CTGACCTGAAAGCCGAGAAG	AGAAGGTGCTAACGAACAGG
GAPDH	ACTCCACTCACGGCAAATTC	TCTCCATGGTGGTGAAGACA
Albumin	ACAGGACACCTGCTCTC	AGTCCTGAGTCCTTCATGTCTTT
F4/80	CTTTGGCTQTGGGCCTTCCAGTC	GCAAGGAGGACAGAGTTTATCGTG
CD11b	ATGGACGCTGATGGCAATACC	TCCCCATTACGTCTCCCA
Acot1	ACTACGATGACCTCCCAAG	CATAGCAAGGCCAAGTTCAC
Cy4a12b	GTTCTACAGATTTCTAGCTCCC	AGAGTCTGCCATGATTTCCG
Cy4a31	CACTCATTCTGCCCTTCTC	ACAATCACCTTCAGCTCACTC
Acaca	AAGGCTATGTGAAGGATGTGG	CTGTCTGAAGAGGTTAGGGAAG
Pcsk9	TTTTATGACCTCTTCCCTGGC	ATTCGCTCCAGGTTCCATG
Mrpl53	TCAAGCTGGTTCGAGTTCAG	ACAGAGCAGTTGAGGTTGG
Hspd1	AGTGTTCACTCCATTGTCCC	TGACTGCCACAACCTGAAG
Pltp	CCTGTGCTCTACCATGCTG	ATTCCATATCCAGGTTGCCG
Abca1	TGACATGGTACATCGAAGCC	GATTTCTGACACTCCCTTCTGG
FGF21	ACGACCAAGACACTGAAGC	ACCCAGGATTTGAATGACCC

## 2.7. Microarray and RNA sequencing

The liver of mice fed with either STC (n=6) or HFD (n=6) for 8 weeks were sent to Kompetenzzentrum Fluoreszenz Bioanalytik (Germany) for gene expression analysis using Affymetrix Mouse Exon 1.0 ST Array. RNA was extracted from the liver of mice treated with rAAV-GPR110 and ASO-GPR110 using RNeasy Kits (QIAGEN, Hilden, Germany) according to the instructions. RNA concentration was quantified using NanoDrop™ 2000 Spectrophotometer (Thermo Scientific, Waltham, USA) and RNA quality was assessed using Agilent 2100 Bioanalyzer (Agilent, Santa Clara, USA). 10 µg of total RNA from liver with RNA integrity number (RIN) greater than 7 was used in RNA-seq. RNA-seq was performed by BGI and analyzed by Dr. Tom system (BGI, Shenzhen, China). A heat map was created based on log<sub>2</sub> transformed counts from different samples. To be included in the heat map, genes were required to have at least 1000 counts, totaled over all samples, where and the standard deviation of the log<sub>2</sub> had to exceed two.

## 2.8. Human samples

Liver biopsy specimens were collected from 9 biopsy-proven NAFLD patients [33]. Liver sections with H&E staining were subjected to histological evaluation of steatosis. Simple steatosis was defined by the presence of macrovascular steatosis affecting at least 5% of hepatocytes without inflammatory foci and evidence of hepatocellular injury in the form of hepatocyte ballooning [34]. Individuals with a heavy alcohol-drinking history ( $\geq 40$  g/day for up to 2 weeks), drug-induced liver disease and hepatitis virus infection were excluded from the study. Clinical parameters of individuals were summarized in Table S1. The human study is approved by the Zhujiang Hospital, Southern Medical University, Guangzhou, China (Number: 2019-KY-097-01). Written informed consent was obtained from participants prior to their inclusion in the study.

## 2.9. Statistical analysis

All experiments were performed at least twice, and each experimental group included  $n \geq 7$  mice. Representative data were presented as mean  $\pm$  standard error of mean (SEM). All statistical analysis was performed with the Graphpad Prism software (version 9.0, CA, USA). Statistical differences among two groups were performed using the unpaired Student t test or Mann-Whitney tests for the comparison of variables with or without normal distribution, respectively. The correlation between the two groups was assessed by non-parametric Spearman's test. For multiple comparisons between three or more groups, one-way ANOVA with Bonferroni correction was conducted. In all statistical comparisons, p values  $< 0.05$  were accepted as significant.

### 3. Results

#### 3.1. GPR110 mainly expresses in liver of mice and its expression is downregulated after HFD treatment.

Firstly, we used microarray analysis to examine the change in expression levels of hepatic GPCRs in mice after HFD treatment (Table S3). In this screening, we found that GPR110 is mainly expressed in liver and its expression is dramatically decreased in the HFD-fed mice as compared to their STC-fed littermates. Remarkably, in agreement with previous studies [20, 35], GPR110 is mainly expressed in the liver of adult mice (Figure 1A-B). We also checked the GPR110 protein expression in those tissues by Western blot analysis. GPR110 proteins were mainly detected in liver and kidney samples (Figure 1B). Next, we used cell fractionation to identify the GPR110 expressing cells in liver (Figure 1C). The CD11b mRNAs were used as markers for non-parenchymal cells (NPC), and albumin mRNA for hepatocytes. Our cell fractionation clearly demonstrated that GPR110 mRNA is mainly expressed in hepatocytes (Figure 1C). This finding was further supported by Western blot analysis (Figure 1D). Remarkably, after HFD treatment for 8 weeks, the expression level of hepatic GPR110 declined to almost undetectable level as examined by qPCR analysis (Figure 1E). In contrast, the mRNA levels of two NAFLD related markers, FGF21 and F4/80 (also known as ADGRE1) were highly induced in the livers of HFD fed mice [36, 37]. Western blot analysis was performed to confirm the declined expression of GPR110 is also observed in protein level in the livers of HFD-fed mice (Figure 1F, upper panel). Interestingly, HFD-treatment did not affect the renal GPR110 expression (Figure 1F, lower panel). Collectively, the hepatic, but not renal, GPR110 level is tightly regulated by nutritional status.

#### 3.2. Overexpression of GPR110 in hepatocytes accelerates metabolic dysregulation caused by HFD.

Based on the dramatic difference in expression levels of hepatic GPR110 before and after HFD treatment, we hypothesized that downregulation of GPR110 in HFD-fed mice may be involved in the pathogenesis of fatty liver. To evaluate the impacts of high hepatic GPR110 level on liver metabolism, GPR110 was overexpressed in the hepatocytes of HFD-fed mice by liver-directed rAAV/ApoE-mediated gene expression system (Figure 2A and S1A). The overexpression of GPR110 in the livers

of the mice were validated by qPCR (Figure 2B and S1B) and Western blot analysis (Figure S1C). We also confirmed that rAAV-mediated GPR110 overexpression was solely in hepatocytes, but not in NPC, by Western blot analysis after cell fractionation (Figure 2C). Renal GPR110 expression level was not affected by liver-directed rAAV/ApoE-mediated gene expression (Figure S1C).

Overexpressing GPR110 in the liver of STC-fed mice did not affect body weight (Figure S1D), fasting glucose level (Figure S1E), fasting insulin level (Figure S1F) and homeostatic model assessment for insulin resistance (HOMA-IR; Figure S1G). There was only a slight increase at several time points in the glucose excursion curve in response to the GTT (Figure S1H) and hepatic glucose production induced by sodium pyruvate in PTT (Figure S1I). No change in insulin sensitivity was observed by insulin tolerance test between STC-fed rAAV-GFP and rAAV-GPR110 mice (Figure S1J).

However, under HFD treatment, rAAV-GPR110 mice gained more body weight (Figure 2D), and body fat mass (Figure 2E-F) than their rAAV-GFP controls. The HFD-fed rAAV-GPR110 mice also had higher fasting glucose level (Figure 2G), fasting insulin level (Figure 2H) and HOMA-IR (Figure 2I). Worsen glucose tolerance was observed in HFD-fed rAAV-GPR110 mice (Figure 2J). Overexpression of GPR110 in livers significantly increased hepatic glucose production induced in PTT (Figure 2K). ITT showed that the glucose levels in HFD-fed rAAV-GPR110 mice remained insensitive at 30 to 60 minutes after injection of insulin as compared to their control HFD-fed rAAV-GFP littermates (Figure 2L). In summary, we observed a mild impairment in glucose homeostasis associated with overexpressing GPR110 in the livers of STC-fed mice and more dramatic impairment was observed when the rAAV-GPR110 mice was challenged with HFD as compared to their rAAV-GFP controls.

### 3.3. Suppressing GPR110 improves glucose homeostasis in HFD-fed rAAV-GPR110 mice

To confirm that the observations above were due to the rAAV-mediated overexpression of hepatic GPR110 in HFD-fed mice, we used two N-acetylgalactosamine (GalNAc) conjugated antisense oligonucleotides (ASO-GPR110s) that bind to different regions of GPR110 mRNAs to knockdown the hepatic GPR110 expression in mice (Figure 3A and S2A). To avoid the observation is due to off-target

effects, two different sequences of ASO were used. Chronic treatment of either ASO-GPR110s only lowered the hepatic, but not renal, GPR110 mRNA (Figure 3B and S2B) and protein (Figure S2C) levels. It is due to the fact that liver hepatocytes abundantly and specifically express the asialoglycoprotein receptor that binds and uptakes circulating glycosylated oligonucleotides via receptor-mediated endocytosis [38]. Knockdown hepatic GPR110 by ASO-GPR110s in STC-fed mice did not affect body weight (Figure S2D) and fasting glucose (Figure S2E), but slightly lowered insulin level (Figure S2F) and HOMR-IR (Figure S2G) as compared to their littermates injected with the negative control – scrambled antisense oligonucleotides (ASO-NC). No difference in the changes of glucose levels in GTT (Figure S2H), PTT (Figure S2I) and ITT (Figure S2J) for both ASO-GPR110s and ASO-NC groups under STC feeding conditions.

In contrast, chronic ASO-GPR110 treatment for 4 weeks significantly decreased their body weight (Figure 3D), fat mass ratio (Figure 3E-F) fasting glucose level (Figure 3G), fasting insulin level (Figure 3H) and HOMA-IR (Figure 3I) in HFD-fed rAAV-GPR110 mice. In addition, treatment of ASO-GPR110s improved glucose tolerance, pyruvate tolerance and insulin sensitivity in HFD-fed rAAV-GPR110 mice as demonstrated by GTT (Figure 3J), PTT (Figure 3K) and ITT (Figure 3L) as compared to ASO-NC controls. In consistent to overexpressing GPR110 in livers, the depletion of hepatic GPR110 by ASOs improves glucose homeostasis in HFD-fed mice.

### 3.4. Treatment of ASO-GPR110s alleviates lipid abundance and liver damage in HFD-fed rAAV-GPR110 mice

We also checked the circulating lipid profiles of the mice. HFD-fed rAAV-GPR110 mice had higher circulating cholesterol (CHO; Figure 4A) and triglyceride (TG; Figure 4B) levels than HFD-fed rAAV-GFP littermates, but their circulating free fatty acid (FFA) levels were similar (Figure 4C). High-density lipoprotein (HDL) cholesterol level was decreased, and low-density lipoprotein (LDL) cholesterol level was increased in HFD-fed rAAV-GRP110-NC mice as compared to chronic ASO-GPR110 treatment group (Figure 4D).

Remarkably, chronic ASO-GPR110 treatment could lower circulating levels of the liver enzymes aspartate transaminase (AST) and alanine aminotransaminase (ALT), as markers of liver damage and hepatotoxicity, in HFD-fed rAAV-GRP110-NC mice (Figure 4E). After sacrificing the mice, we examined their hepatic lipid profiles. We found the livers of HFD-fed rAAV-GRP110 mice were significantly heavier (Figure 4F) and paler (Figure 4G, upper panels) than the livers of their rAAV-GFP littermates and ASO-GPR110 treated rAAV-GRP110 mice. Consistent with these observations, HFD-induced lipid accumulation within hepatocytes were substantially more abundant in the livers of HFD-fed rAAV-GPR110 mice than the rAAV-GFP littermates as determined by haematoxylin and eosin (H&E) staining and Oil Red O staining (Figure 4G, upper and middle rows). Moreover, based on the Masson trichrome staining, more fibre extension and larger fibrous septa formation was observed for the liver samples of rAAV-GPR110 mice as compared to the livers from rAAV-GFP littermates (Figure 4G, lower row). These alterations were remarkably reduced after ASO-GPR110 treatments (Figure 4G). Like the circulating lipid profiles mentioned above, treatment of ASO-GPR110s for 8 weeks could improve the hepatic lipid profiles of rAAV-GRP110 mice in terms of CHO (Figure 4H), TG (Figure 4I) and FFA (Figure 4J). Altogether, overexpression of hepatic GPR110 in mice is sufficient to perturb lipid metabolism and hence the progression of NAFLD especially in obese subjects.

### 3.5. The metabolic dysregulation of rAAV-GRP110 mice is correlated to the upregulation SCD1 expression

To reveal the molecular mechanism underlying the involvement of hepatic GPR110 in NAFLD development, RNA-sequencing analysis was performed on RNA samples extracted from the livers of HFD-fed ASO-NC treated rAAV-GPF, ASO-NC treated rAAV-GPR110 and ASO-GRP110 treated rAAV-GPP110 mice. In the search for the molecular processes for metabolisms, several lipid metabolism-related genes were altered (Figure 5A-B). We subsequently used RT-qPCR to confirm the RNA sequencing results (Figure 5C). Among them, we are particularly interested in stearoyl CoA desaturase 1 (SCD1). SCD1 is a key lipogenic enzyme responsible for the rate-limiting step in the synthesis of monounsaturated fatty acids (MUFAs), such as oleate and palmitoleate, by forming double

bonds in saturated fatty acids [39]. MUFAs serve as substrates for the synthesis of various kinds of lipids and increases in SCD1 activity is involved in the development of NAFLD, hypertriglyceridemia, atherosclerosis, and diabetes [40, 41].

### 3.6. The upregulation of SCD1 expression in liver is driven by the presence of GPR110

To confirm SCD1 expression is induced by GPR110, *in vitro* assays were performed by using adenovirus-mediated GPR110 expression system (ADV-GPR110) to overexpress GPR110 in primary hepatocytes isolated from STC-fed mice. After infection, the expressions of SCD1 mRNAs (Figure 6A) and protein (Figure 6B) were dramatically induced, but not in control group which was treated with ADV-GFP. In addition, the GPR110 specific ASOs can not only knockdown the GPR110 expression, but also induced the SCD1 expression by increasing GPR110 in the ADV-GPR110 primary hepatocytes (Figure 6A-B). *In vitro* luciferase reporter assay was performed to further validate the expression of SCD1 is transcriptional regulated by GPR110. We constructed plasmid harbouring luciferase gene driven by the mouse SCD1 promoter (-2000 to +100) and transfected into HEK293 cells. There was no change of luciferase activity of pGL3- SCD1 promoter-luciferase transfected HEK293 cells under the treatment of GPR110 ligand DHEA, unless the HEK293 cells were pre-infected with adenovirus overexpressing GPR110 (ADV-GPR110; Figure 6C). The overexpression of GPR110 in ADV-GPR110 infected cells and inductions of SCD1 mRNA expression by treatment of DHEA were also validated by qPCR (Figure 6D). The changes in hepatocyte lipid profiles by the expression level of GPR110 and SCD1 were also checked. In agreement with our *in vivo* studies' findings, the overexpression of GPR110 increased the intracellular CHO (Figure 6E), TG (Figure 6F) and FFA (Figure 6G). Their increases could be completely repressed by ASO against GPR110 (Figure 6E-G) and partially repressed by overexpressing SCD1 specific shRNAs (Figure 6F-G). In summary, the transcription level of SCD1 is regulated by GPR110. GPR110 enhances the lipid accumulation by inducing SCD1 expression.

### 3.7. Inhibition of SCD1 in rAAV-GPR110 mice partially attenuates most metabolic dysregulations especially lipid profiles

To examine whether the up-regulation of hepatic SCD1 was the cause of metabolic dysregulation in rAAV-GRP110 mice, a liver-specific SCD1 inhibitor MK8245 were used to alleviate the metabolic dysregulation by overexpressing GPR110 in HFD-fed rAAV-GRP110 mice (Figure 7A) [27]. Chronic treatment of MK8245 for 11 weeks did not affect the expression of GPR110 mRNA (Figure 7B) and protein (Figure 7C) levels in rAAV-GRP110 mice. In agreement with previous studies showing that the chronic treatment of this SCD1 inhibitor improves various metabolic parameters including lipid and glucose profiles in various animal models [42], treatment of MK8245 lowered the body weight (Figure 7D), improved glucose homeostasis in term of fasting glucose level (Figure 7E) and HOMR-IR (Figure 7G), and performance in GTT (Figure 7H) and PTT (Figure 7I) of HFD-fed rAAV-GRP110 mice as compared to untreated littermates. But there was no change in insulin sensitivity as demonstrated by ITT (Figure 7J).

MK8245 treatment also lowered the circulating CHO (Figure 8A) and TG (Figure 8B) levels almost to the levels of HFD-fed rAAV-GFP mice, but there was no change in circulating FFA level (Figure 8C). A relatively higher HDL can be found in the MK8245 group but there were no differences detected regarding the LDL level (Figure 8D). The AST and ALT levels were also alleviated in the MK8245 group compared to the rAAV-GPR110 littermates (Figure 8E). MK8245 treatment partially reduced the liver weight (Figure 8F), degree of paleness, severity of fibrosis (Figure 8G) and lipid accumulations (Figure 8H-J). To conclude, treatment of MK8245 could improve the lipid profiles and alleviate metabolic dysregulation caused by overexpression of hepatic GPR110 in mice.

### 3.8. Expression of GPR110 in liver is closely associated with hepatic steatosis in NAFLD patients

To evaluate the clinical relevance of our findings in mice, we first checked the expression level of GPR110 in human liver from a publicized transcriptome dataset Gene Expression Omnibus (GEO; Profile # GDS4881) with human liver biopsy of different phases from control to NAFLD [43]. Healthy



obese subjects without NAFLD had lower GPR110 mRNA expression than healthy lean subjects, but obese NAFLD subjects had similar GPR110 mRNA expression level as healthy lean subjects (Figure 9A). Subsequently, by using the same transcriptome dataset, we investigated the correlation in the expression level of GPR110 and SCD1. The expression level of GPR110 was positively correlated with SCD1 in the liver ( $r = 0.4635$ ,  $P < 0.05$ ; Figure 9B). To verify the observation, we performed immunohistochemistry staining with liver sections from biopsy-proven patients with mild, moderate, and severe NAFLD, respectively (Table S4). The degree of steatosis was determined by non-alcoholic steatohepatitis clinical research network (NASH CRN) scoring system [34]. Immunostaining analysis demonstrated that hepatic expression of GPR110 protein was higher in the ones with severe steatosis than those with lower degree of NAFLD (Figure 9C). These data collectively suggest that GPR110 expression level correlates to hepatic steatosis in humans as well.

#### 4. Discussion

The present study has uncovered a previously unrecognized role of GPR110 in regulating hepatic lipid metabolism. Firstly, we demonstrated that GPR110 is required for regulating lipid content in liver of diet-induced obese mice by both gain-of-function and loss-of-function approaches. HFD-induced steatosis and liver injury were exacerbated in obese mice with high GPR110 overexpression level, and knockdown hepatic GPR110 alleviated the severity of obesity-induced NAFLD. We also confirmed a correlation between hepatic GPR110 expression level and liver steatosis in human. We believe the downregulation of hepatic GPR110 expression level in obese subjects is a protective mechanism to prevent over-accumulation of lipid in liver. It remains to be explored how the transcription level of hepatic GPR110 repressed is in the health obese subjects. In addition, although NAFLD is usually associated with obesity, up to 19% of lean Asian can also present with NAFLD [44]. It is interesting to further explore whether the expression levels of hepatic GPR110 mRNA in these “lean NAFLD” patients are higher than the lean healthy controls.

Subsequently, we also revealed the mechanism which at least in part achieved through the expression of SCD1 in liver. We performed RNA-sequencing analysis to decipher the mechanism and found the expression levels SCD1 mRNAs and protein are dramatically upregulated in the livers of rAAV-GPR110 mice and repressed in GPR110-ASOs treated rAAV-GPR110 mice. SCD1 is the rate-limiting enzyme for catalysing the conversion of saturated long-chain fatty acids into monounsaturated fatty acids. To illustrate that the changes in metabolic phenotype in the rAAV-GPR110 mice were caused by the up-regulation of hepatic SCD1 expression levels, we used SCD1 shRNAs and inhibitor to check whether the metabolic changes can be rescued in GPR110 overexpressing hepatocytes by both *in vivo* and *in vitro* experiments. Concordantly, pharmacologically inhibiting SCD1 by MK8245 was sufficient to rescue the key metabolic dysregulations by overexpressing GPR110 in their livers. Therefore, we concluded that GPR110 induces SCD1 expression, leading to the increase level of *de novo* lipogenesis in liver and exacerbating obese-induced NAFLD.

Previous studies reported that SCD1 global knockout (KO) mice showed improved insulin sensitivity, higher-energy metabolism, and more resistant to diet-induced obesity by the activation of

lipid oxidation in addition to the reduction of triglyceride synthesis and storage [45-47]. In addition, the *ob/ob* mice with SCD1 mutations had significantly reduced storage of triglyceride and lower level of very low-density lipoprotein (VLDL) production [48]. Remarkably, liver-specific KO of SCD1 was sufficient to reduce high-carbohydrate diet-induced adiposity with a significant reduction of hepatic lipogenesis and improved glucose tolerance [46]. Indeed, SCD1 inhibition was proposed to be a therapeutic strategy for the treatment of metabolic syndrome [49].

What are the potential advantages of targeting GPR110 rather than SCD1 for the treatment of NAFLD? First of all, SCD1 is highly expressed in various tissues, especially adipose tissues [50]. In addition, expression level and activity of SCD1 is very tightly regulated [51, 52]. Harmful consequences from inhibiting SCD1 have been reported, such as the inhibition of fat mobilization in adipose tissues, and the promotion of proinflammatory and endoplasmic reticulum stress by accumulation SCD1 substrates [53-56]. These findings clearly documented that optimal level of SCD1 is required to maintain health. Secondly, in contrast to SCD1, according to the phenotypes of GPR110 KO mice in previous studies [20, 22] and a dramatical reduction of GPR110 in the livers of HFD-fed mice and health obese subjects, the hepatic GPR110 may be dispensable in adults. Therefore, targeting hepatic GPR110 is a potential safe treatment of NAFLD. Thirdly, according to our RNA-sequencing analysis, repressing GPR110 can also regulate the expression of many other lipid metabolism genes. Unfortunately, GPR110 antagonist is not available at this moment. As demonstrated in this study, the ASO-based strategy is an alternative approach to knockdown the expression of GPR110 in liver [57].

The current study focuses on GPR110 in hepatic lipid metabolism. As mentioned above, GPR110 is primarily understood to be an oncogene [15-21, 58-61]. Notably, recent study reported that deficiency of GPR110 can decelerate carcinogen-induced hepatocarcinogenesis in adult mice [20]. Coincidentally, high expression level of SCD1 is also genetically susceptible to hepatocarcinogenesis [62]. It is highly possible that GPR110 also accelerates carcinogenesis by inducing SCD1 expression level. To prove this hypothesis, we may check the SCD1 expression level in the GPR110 induced cancers.

In summary, we present evidence demonstrating a novel role of hepatic GPR110 in regulating lipid metabolism and explored the mechanism partially via regulation of SCD1 expression level. As the

amino acid sequencing of GPR110 are highly conserved in humans and mice, targeting GPR110 may serve as a novel therapeutic approach for the treatment of NAFLD patients.

## **Acknowledgement**

This work was supported by National Natural Science Foundation of China (81870586), Area of Excellence (AoE/M-707/18), and General Research Fund (15101520) to C.M.W., and National Natural Science Foundation of China (82270941, 81974117) to S.J. We also thank Dr. Oscar Wong and Prof. Zou Xiang for critical review of this manuscript.

## **Grant support**

This work was supported by the National Natural Science Foundation of China (81870586); Area of Excellence (AoE/M-707/18); and General Research Fund (15101520) to C.M.W., and National Natural Science Foundation of China (82270941, 81974117) to S.J.

## **CRedit authorship contribution statement**

M.W., A.X. and C.M.W. designed the experiments; M.W., T.H.L., C.D., K.Y.C., X.L. and J.L. conducted the experiments and analysed the data; M.W. and C.M.W. drafted the manuscript; L.L., S.J., S.Y. and P.L. provided essential experimental materials; C.M.W. supervised the whole project.

## **Declaration of competing interest**

Nothing to report.

## References

- [1] Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016;64:73-84.
- [2] Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. *Gastroenterology* 2020;158:1851-1864.
- [3] Peng C, Stewart AG, Woodman OL, Ritchie RH, Qin CX. Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments. *Front Pharmacol* 2020;11:603926.
- [4] Allen AM, Hicks SB, Mara KC, Larson JJ, Therneau TM. The Risk of Incident Extrahepatic Cancers is higher in Nonalcoholic Fatty Liver Disease than Obesity - a Longitudinal Cohort Study. *J Hepatol* 2019.
- [5] Zhou F, Zhou J, Wang W, Zhang XJ, Ji YX, Zhang P, et al. Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta-Analysis. *Hepatology* 2019;70:1119-1133.
- [6] Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. *Nat Rev Gastroenterol Hepatol* 2016;13:196-205.
- [7] Yang D, Zhou Q, Labroska V, Qin S, Darbalaei S, Wu Y, et al. G protein-coupled receptors: structure- and function-based drug discovery. *Signal Transduct Target Ther* 2021;6:7.
- [8] Hauser AS, Attwood MM, Rask-Andersen M, Schioth HB, Gloriam DE. Trends in GPCR drug discovery: new agents, targets and indications. *Nature reviews Drug discovery* 2017;16:829-842.
- [9] Sriram K, Insel PA. G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs? *Molecular pharmacology* 2018;93:251-258.
- [10] Yang M, Zhang CY. G protein-coupled receptors as potential targets for nonalcoholic fatty liver disease treatment. *World J Gastroenterol* 2021;27:677-691.
- [11] Kurtz R, Anderman MF, Shepard BD. GPCRs get fatty: the role of G protein-coupled receptor signaling in the development and progression of nonalcoholic fatty liver disease. *American journal of physiology Gastrointestinal and liver physiology* 2021;320:G304-G318.
- [12] Fredriksson R, Lagerstrom MC, Hoglund PJ, Schioth HB. Novel human G protein-coupled receptors with long N-terminals containing GPS domains and Ser/Thr-rich regions. *FEBS letters* 2002;531:407-414.
- [13] Bjarnadottir TK, Fredriksson R, Hoglund PJ, Gloriam DE, Lagerstrom MC, Schioth HB. The human and mouse repertoire of the adhesion family of G-protein-coupled receptors. *Genomics* 2004;84:23-33.
- [14] Bjarnadottir TK, Geirardsdottir K, Ingemansson M, Mirza MA, Fredriksson R, Schioth HB. Identification of novel splice variants of Adhesion G protein-coupled receptors. *Gene* 2007;387:38-48.
- [15] Lum AM, Wang BB, Beck-Engeser GB, Li L, Channa N, Wabl M. Orphan receptor GPR110, an oncogene overexpressed in lung and prostate cancer. *BMC cancer* 2010;10:40.


- [16] Liu Z, Zhang G, Zhao C, Li J. Clinical Significance of G Protein-Coupled Receptor 110 (GPR110) as a Novel Prognostic Biomarker in Osteosarcoma. *Medical science monitor : international medical journal of experimental and clinical research* 2018;24:5216-5224.
- [17] Zhu X, Huang G, Jin P. Clinicopathological and prognostic significance of aberrant G protein-coupled receptor 110 (GPR110) expression in gastric cancer. *Pathology, research and practice* 2019;215:539-545.
- [18] Shi H, Zhang S. Expression and prognostic role of orphan receptor GPR110 in glioma. *Biochem Biophys Res Commun* 2017;491:349-354.
- [19] Bhat RR, Yadav P, Sahay D, Bhargava DK, Creighton CJ, Yazdanfard S, et al. GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. *Breast cancer research and treatment* 2018;170:279-292.
- [20] Ma B, Zhu J, Tan J, Mao Y, Tang L, Shen C, et al. Gpr110 deficiency decelerates carcinogen-induced hepatocarcinogenesis via activation of the IL-6/STAT3 pathway. *Am J Cancer Res* 2017;7:433-447.
- [21] Nam HJ, Kim YJ, Kang JH, Lee SJ. GPR110 promotes progression and metastasis of triple-negative breast cancer. *Cell Death Discov* 2022;8:271.
- [22] Lee JW, Huang BX, Kwon H, Rashid MA, Kharebava G, Desai A, et al. Orphan GPR110 (ADGRF1) targeted by N-docosahexaenylethanolamine in development of neurons and cognitive function. *Nature communications* 2016;7:13123.
- [23] Nakamura A, Terauchi Y. Lessons from mouse models of high-fat diet-induced NAFLD. *International journal of molecular sciences* 2013;14:21240-21257.
- [24] Sellmann C, Baumann A, Brandt A, Jin CJ, Nier A, Bergheim I. Oral Supplementation of Glutamine Attenuates the Progression of Nonalcoholic Steatohepatitis in C57BL/6J Mice. *The Journal of nutrition* 2017;147:2041-2049.
- [25] Lee JT, Huang Z, Pan K, Zhang HJ, Woo CW, Xu A, et al. Adipose-derived lipocalin 14 alleviates hyperglycaemia by suppressing both adipocyte glycerol efflux and hepatic gluconeogenesis in mice. *Diabetologia* 2016;59:604-613.
- [26] Cheng Y, Kang XZ, Cheng T, Ye ZW, Tipoe GL, Yu CH, et al. FACL1 is a Novel CREB-H-Induced Protein That Inhibits Intestinal Lipid Absorption and Reverses Diet-Induced Obesity. *Cell Mol Gastroenterol Hepatol* 2022;13:1365-1391.
- [27] Iida T, Ubukata M, Mitani I, Nakagawa Y, Maeda K, Imai H, et al. Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity. *European journal of medicinal chemistry* 2018;158:832-852.
- [28] Xu L, Huang Z, Lo T-h, Lee JTH, Yang R, Yan X, et al. Hepatic PRMT1 ameliorates diet-induced hepatic steatosis via induction of PGC1 $\alpha$ . *Theranostics* 2022;12:2502.
- [29] Huang Z, Zhong L, Lee JTH, Zhang J, Wu D, Geng L, et al. The FGF21-CCL11 Axis Mediates Beiging of White Adipose Tissues by Coupling Sympathetic Nervous System to Type 2 Immunity. *Cell Metab* 2017;26:493-508 e494.

- [30] Wong CM, Wang Y, Lee JT, Huang Z, Wu D, Xu A, et al. Adropin is a brain membrane-bound protein regulating physical activity via the NB-3/Notch signaling pathway in mice. *J Biol Chem* 2014;289:25976-25986.
- [31] Ye D, Li H, Wang Y, Jia W, Zhou J, Fan J, et al. Circulating Fibroblast Growth Factor 21 Is A Sensitive Biomarker for Severe Ischemia/reperfusion Injury in Patients with Liver Transplantation. *Sci Rep* 2016;6:19776.
- [32] Chen J, Li J, Yiu JHC, Lam JKW, Wong CM, Dorweiler B, et al. TRIF-dependent Toll-like receptor signaling suppresses Scd1 transcription in hepatocytes and prevents diet-induced hepatic steatosis. *Sci Signal* 2017;10.
- [33] Xu L, Huang Z, Lo TH, Lee JTH, Yang R, Yan X, et al. Hepatic PRMT1 ameliorates diet-induced hepatic steatosis via induction of PGC1alpha. *Theranostics* 2022;12:2502-2518.
- [34] Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. *The American journal of gastroenterology* 1999;94:2467-2474.
- [35] Promel S, Waller-Evans H, Dixon J, Zahn D, Colledge WH, Doran J, et al. Characterization and functional study of a cluster of four highly conserved orphan adhesion-GPCR in mouse. *Developmental dynamics : an official publication of the American Association of Anatomists* 2012;241:1591-1602.
- [36] Rusli F, Deelen J, Andriyani E, Boekschoten MV, Lute C, van den Akker EB, et al. Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice. *Sci Rep* 2016;6:30484.
- [37] Kopec AK, Abrahams SR, Thornton S, Palumbo JS, Mullins ES, Divanovic S, et al. Thrombin promotes diet-induced obesity through fibrin-driven inflammation. *J Clin Invest* 2017;127:3152-3166.
- [38] Cui H, Zhu X, Li S, Wang P, Fang J. Liver-Targeted Delivery of Oligonucleotides with N-Acetylgalactosamine Conjugation. *ACS Omega* 2021;6:16259-16265.
- [39] Paton CM, Ntambi JM. Biochemical and physiological function of stearoyl-CoA desaturase. *American journal of physiology Endocrinology and metabolism* 2009;297:E28-37.
- [40] Kotronen A, Seppanen-Laakso T, Westerbacka J, Kiviluoto T, Arola J, Ruskeepaa AL, et al. Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. *Diabetes* 2009;58:203-208.
- [41] Mar-Heyming R, Miyazaki M, Weissglas-Volkov D, Kolaitis NA, Sadaat N, Plaisier C, et al. Association of stearoyl-CoA desaturase 1 activity with familial combined hyperlipidemia. *Arterioscler Thromb Vasc Biol* 2008;28:1193-1199.
- [42] Oballa RM, Belair L, Black WC, Bleasby K, Chan CC, Desroches C, et al. Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. *Journal of medicinal chemistry* 2011;54:5082-5096.

- [43] Ahrens M, Ammerpohl O, von Schonfels W, Kolarova J, Bens S, Itzel T, et al. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. *Cell Metab* 2013;18:296-302.
- [44] VanWagner LB, Armstrong MJ. Lean NAFLD: A not so benign condition? *Hepatol Commun* 2018;2:5-8.
- [45] Ntambi JM, Miyazaki M, Stoeckl JP, Lan H, Kendziora CM, Yandell BS, et al. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. *Proc Natl Acad Sci U S A* 2002;99:11482-11486.
- [46] Miyazaki M, Flowers MT, Sampath H, Chu K, Otzelberger C, Liu X, et al. Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. *Cell Metab* 2007;6:484-496.
- [47] Miyazaki M, Sampath H, Liu X, Flowers MT, Chu K, Dobryzn A, et al. Stearoyl-CoA desaturase-1 deficiency attenuates obesity and insulin resistance in leptin-resistant obese mice. *Biochem Biophys Res Commun* 2009;380:818-822.
- [48] Cohen P, Miyazaki M, Socci ND, Hagge-Greenberg A, Liedtke W, Soukas AA, et al. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. *Science* 2002;297:240-243.
- [49] Jiang G, Li Z, Liu F, Ellsworth K, Dallas-Yang Q, Wu M, et al. Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. *J Clin Invest* 2005;115:1030-1038.
- [50] Ascenzi F, De Vitis C, Maugeri-Sacca M, Napoli C, Ciliberto G, Mancini R. SCD1, autophagy and cancer: implications for therapy. *Journal of experimental & clinical cancer research : CR* 2021;40:265.
- [51] AM AL, Syed DN, Ntambi JM. Insights into Stearoyl-CoA Desaturase-1 Regulation of Systemic Metabolism. *Trends in endocrinology and metabolism: TEM* 2017;28:831-842.
- [52] Mauvoisin D, Mounier C. Hormonal and nutritional regulation of SCD1 gene expression. *Biochimie* 2011;93:78-86.
- [53] Brown JM, Rudel LL. Stearoyl-coenzyme A desaturase 1 inhibition and the metabolic syndrome: considerations for future drug discovery. *Current opinion in lipidology* 2010;21:192-197.
- [54] Leung JY, Kim WY. Stearoyl co-A desaturase 1 as a ccRCC therapeutic target: death by stress. *Clin Cancer Res* 2013;19:3111-3113.
- [55] Liu X, Strable MS, Ntambi JM. Stearoyl CoA desaturase 1: role in cellular inflammation and stress. *Adv Nutr* 2011;2:15-22.
- [56] Zou Y, Wang YN, Ma H, He ZH, Tang Y, Guo L, et al. SCD1 promotes lipid mobilization in subcutaneous white adipose tissue. *Journal of lipid research* 2020;61:1589-1604.
- [57] Dhuri K, Bechtold C, Quijano E, Pham H, Gupta A, Vikram A, et al. Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development. *J Clin Med* 2020;9.
- [58] Abdulkareem NM, Bhat R, Qin L, Vasaikar S, Gopinathan A, Mitchell T, et al. A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2-positive breast cancer. *The FASEB journal : official publication of the Federation of American Societies for Experimental Biology* 2021;35:e21719.




- [59] Sadras T, Heatley SL, Kok CH, Dang P, Galbraith KM, McClure BJ, et al. Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions. *Cancer letters* 2017;408:92-101.
- [60] Espinal-Enriquez J, Munoz-Montero S, Imaz-Rosshandler I, Huerta-Verde A, Mejia C, Hernandez-Lemus E. Genome-wide expression analysis suggests a crucial role of dysregulation of matrix metalloproteinases pathway in undifferentiated thyroid carcinoma. *BMC genomics* 2015;16:207.
- [61] Harvey RC, Mullighan CG, Wang X, Dobbin KK, Davidson GS, Bedrick EJ, et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. *Blood* 2010;116:4874-4884.
- [62] Falvella FS, Pascale RM, Gariboldi M, Manenti G, De Miglio MR, Simile MM, et al. Stearoyl-CoA desaturase 1 (Scd1) gene overexpression is associated with genetic predisposition to hepatocarcinogenesis in mice and rats. *Carcinogenesis* 2002;23:1933-1936.




**Figure 1: GPR110 is mainly expressed in the liver and its expression is downregulated after HFD treatment.** Eight-week-old male C57BL/6J mice were fed with either STC or HFD for 8 weeks. (A) mRNA expression levels of GPR110 in different organs as determined by qPCR analysis (n = 5). (B) Representative immunoblotting analyses of GPR110 expression in different tissues of C57BL/J mice after STC for 8 weeks (n = 3). (C) mRNA expression levels of GPR110, CD11b and albumin in fractions of hepatocyte or NPC isolated from STC-fed mice livers as determined by qPCR. (D) Left panel: representative immunoblotting analyses of GPR110, CD11b and albumin in fractions of hepatocytes or NPC isolated from mice livers fed with STC, each lane is a sample from different individual; right panel: quantification of protein expression levels of GPR110, CD11b and albumin. Protein expression levels were normalized to the expression of  $\beta$ -actin. The fraction of Hepatocytes was set as 1 for fold-change calculation. (E) mRNA expression levels of GPR110, FGF21 and F4/80 (served as HFD marker) in mice livers fed with either STC or HFD for 8 weeks as determined by qPCR. (F) Left panel: representative immunoblotting analyses of GPR110 in mice fed with either STC or HFD for 8 weeks; right panel: quantification of protein

expression levels of GPR110. Protein expression levels were normalized to the expression of  $\beta$ -tubulin. The sample from STC mice were set as 1 for fold-change calculation. Each lane is a sample from different individual. GPR110, G-protein coupled receptor 110; STC, standard chow diet; HFD, high-fat diet; NPC, non-parenchymal cell. Data represents as mean  $\pm$  SEM; n = 8 per group; repeated with three independent experiments; P value analyzed by two-tailed Student's t test. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.




**Figure 2: Overexpression of GPR110 in hepatocytes exaggerates metabolic dysregulation by HFD treatment.** Eight-week-old male C57BL/6J mice were infected with  $3 \times 10^{11}$  copies of rAAV encoding GPR110 (rAAV-GPR110, i.v.) or control (rAAV-GFP, i.v.) and received HFD feeding, respectively. (A) Schematic illustration of viral treatments. (B) Hepatic mRNA expression levels of GPR110 from rAAV-GPR110 mice liver in fractions of hepatocyte or NPC isolated from HFD-fed mice livers as determined by qPCR. (C) Immunoblotting analyses of GPR110, CD11b and albumin from rAAV-GPR110 mice liver in fractions of hepatocyte or NPC isolated from HFD-fed mice livers. Each lane is a sample from a different individual. n = 3 per group. (D) Body weight, (E) the percentage of fat mass and (F) lean mass were assessed in different groups. (G) Fasting blood glucose level were measured biweekly upon rAAV injection. (H) The fasting serum insulin level and (I) HOMA-IR index were measured and calculated according to the

formula  $[\text{Fasting blood glucose (mmol/l)} \times \text{Fasting blood insulin (mIU/l)}] / 22.5$  for the HFD-fed rAAV-GPR110 or rAAV-GFP mice at the end of the experiment (J) GTT (1 g/kg BW, left) and area under curve (AUC, right) of serum glucose at week 10. (K) PTT (1 g/kg BW, left) and AUC (right) of serum glucose at week 11. (L) ITT (0.5 U/kg BW, left) and AUC (right) of serum glucose at week 12. mRNA expression levels of the target genes were normalized to the expression of mouse GAPDH. rAAV-NC group was set as 1 for fold-change calculation. GPR110, G-protein coupled receptor 110; STC, standard chow diet; HFD, high-fat diet; NPC, non-parenchymal cell; BW, body weight; GTT, glucose tolerance test; PTT, pyruvate tolerance test; ITT, insulin tolerance test; AUC, area under curve; NC, negative control; HOMA-IR, homeostasis model assessment-estimated insulin resistance. Data represents as mean  $\pm$  SEM; n = 8 mice per group; repeated with three independent experiments; P value analyzed by two-tailed Student's t test. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.



**Figure 3: Deletion of hepatic GPR110 protects against diet-induced glucose intolerance in GPR110 overexpress mice.** Eight-week-old male C57BL/6J mice were infected with either  $3 \times 10^{11}$  copies of rAAV encoding GPR110 (rAAV-GPR110, i.v.) or control (rAAV-GFP, i.v.) and two different sequences of GPR110 ASO (ASO1-GPR110, ASO2-GPR110, 5 mg/kg BW, one dose per week, s.c.) or scrambled control (ASO-NC, s.c.) received HFD feeding, respectively. (A) Schematic illustration of viral treatments. (B) Hepatic mRNA expression levels of GPR110 from different groups of mice received either GFP-NC, GPR110-NC, GPR110-ASO1 or GPR110-ASO2 fed with HFD, respectively, as determined by qPCR analysis. (C) Left panel: Immunoblotting analyses of GPR110 and β-tubulin from livers of HFD-fed rAAV-GFP or rAAV-GPR110 mice treated with either ASO-NC or ASO-GPR110. Each lane is a sample from a different individual. Right panel: quantification of protein expression levels of GPR110 and β-tubulin. Protein expression levels were normalized to the expression of β-tubulin. n = 3 per group. (D) Body weight was measured biweekly upon rAAV and ASO injection. (E) The percentage of fat mass and (F) the percentage of lean mass were measured at the end of the experiment. (G) The fasting blood glucose level of different


groups were measured upon rAAV and ASO injection. (H) Fasting serum insulin level and (I) HOMA-IR index were measured and calculated according to the formula  $[\text{Fasting blood glucose (mmol/l)} \times \text{Fasting blood insulin (mIU/l)}] / 22.5$  for the HFD-fed rAAV-GPR110 or rAAV-GFP mice at the end of the experiment. (J) GTT (1 g/kg BW, left) and AUC (right) of serum glucose at week 10. (K) PTT (1 g/kg BW, left) and AUC (right) of serum glucose at week 11. (L) ITT (0.5 U/kg BW, left) and AUC (right) of serum glucose at week 12. mRNA expression levels of the target genes were normalized to the expression of mouse GAPDH. rAAV-NC group was set as 1 for fold-change calculation. STC, standard chow diet; HFD, high-fat diet; ASO, antisense oligonucleotides; BW, body weight; GTT, glucose tolerance test; PTT, pyruvate tolerance test; ITT, insulin tolerance test; AUC, area under curve; NC, negative control; HOMA-IR, homeostasis model assessment-estimated insulin resistance. Data represents as mean  $\pm$  SEM; n = 8 mice per group; repeated with three independent experiments; P value analyzed by two-tailed Student's t test. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.



**Figure 4: Up-regulation of hepatic GPR110 exaggerates liver steatosis in HFD mice fed with HFD while down-regulation of hepatic GPR110 protects mice from diet-induced liver lipid accumulation.** Eight-week-old male C57BL/6J mice were infected with either  $3 \times 10^{11}$  copies of rAAV encoding GPR110 (rAAV-GPR110, i.v.) or control (rAAV-NC, i.v.) and two different sequences of GPR110 antisense oligonucleotides (ASO1-GPR110, ASO2-GPR110, 5 mg/kg BW, one dose per week, s.c.) or scrambled control (ASO-NC, s.c.) received HFD feeding, respectively. (A) Serum cholesterol (CHO), (B) serum triglyceride (TG) and (C) serum free fatty acid (FFA) levels were measured at week 13. (D) Serum high-density lipoprotein (HDL) and low-density lipoprotein (LDL). (E) The levels of serum aspartate transaminase (AST) alanine transaminase (ALT). (F) The ratio of the liver weight against body weight was calculated after




sacrificing the mice from four different groups. (G) Representative gross pictures of liver tissues (upper panels), representative images of H&E (middle panels) and Oil Red O (lower panels) staining of liver sections (200  $\mu$ m). The percentage of lipid area according to H&E staining (right panel); n = 3 per group. (H) Hepatic CHO, (I) hepatic TG and (J) hepatic FFA were normalized by the weight of liver samples used for lipid extraction. i.v., intravenous injection; s.c., subcutaneous injection; STC, standard chow diet; HFD, high-fat diet; ASO, antisense oligonucleotides; BW, body weight; CHO, cholesterol; TG, triglyceride; FFA, free fatty acid; HDL, high-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate transaminase; ALT, alanine transaminase; H&E, hematoxylin-eosin. Data represents as mean  $\pm$  SEM; n = 8 mice per group; repeated with three independent experiments; P value analyzed by two-tailed Student's t test. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.




**Figure 5: GPR110 is a major regulator of hepatic lipid metabolism.** Eight-week-old male C57BL/6J mice were infected with either  $3 \times 10^{11}$  copies of rAAV encoding GPR110 (rAAV-GPR110, i.v.) or control (rAAV-NC, i.v.) and two GPR110 antisense oligonucleotides (ASO1-GPR110, ASO2-GPR110, 5 mg/kg BW, one dose per week, s.c.) or scrambled control (ASO-NC, s.c.) and received HFD feeding, respectively. Mice were sacrificed and mRNA of liver from each group were extracted and RNA-seq analysis was conducted. (A) KEGG pathway assay of differential mRNA transcripts in rAAV and ASO groups identified by RNA-seq. (B) Heat map show the Log<sub>2</sub> scale fold change in the expression levels of a set of genes involved in lipid metabolism from RNA seq data of livers in HFD-fed mice treated by rAAV-GPR110 or rAAV-GPR110 plus GPR110-ASO1. n = 3 per group. (C) mRNA expression levels of genes according to the heatmap from different groups of mice received either GFP-NC, GPR110-NC, GPR110-ASO1 or GPR110-ASO2 fed with HFD, respectively, as determined by qPCR analysis, n = 6 mice per group. STC, standard chow diet; HFD, high-fat diet; i.v., intravenous injection; s.c., subcutaneous injection; ASO, antisense oligonucleotides; KEGG, Kyoto Encyclopedia of Genes and Genomes; GEO, gene expression omnibus; NAFLD, non-

alcoholic fatty liver disease. Data represents as mean  $\pm$  SEM; P value analyzed by two-tailed Student's t test. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.




**Figure 6: SCD1 expression is regulated by GPR110 in primary hepatocytes.** Primary hepatocytes were isolated from eight-week-old male C57BL/6J mice with STC. (A) Primary hepatocytes were infected with either adenoviral vector expressing GPR110 (ADV-GPR110) or control adenovirus expressing GFP (ADV-GFP) 24h after plating, followed by transfection with ASO1-GPR110, ASO2-GPR110 or ASO-NC for another 6 hours. mRNA expression levels of GPR110 and SCD1 from different groups were assessed, as determined by qPCR analysis. (B) Left panel: immunoblotting analysis for the expression level of GPR110 and SCD1 from different groups of primary hepatocytes. Right panel: quantification of protein expression levels of GPR110 and SCD1. Protein expression levels were normalized to the expression of  $\beta$ -tubulin. Each lane is a sample from a different plate. Right panel: quantification of protein expression levels of GPR110, SCD1 and  $\beta$ -tubulin. n = 3 per group. Protein expression levels were normalized to the expression of  $\beta$ -tubulin. The samples for GFP were set as 1 for fold-change calculation. (C-D) HEK293 cells were infected with pGL3-SCD1 promoter-luciferase plasmid and adenoviral vector expressing GPR110 (ADV-GPR110) or GFP (ADV-GFP) for 48 h and DHEA was added to the transfected cells at the concentration

of 100  $\mu$ M for 24 h. Cell lysates were used for (C) luciferase assay or (D) qPCR analysis. Lysates from the cell co-transfection with pGL3-SCD1 promoter-luciferase plasmid and ADV-GFP without treatment of DHEA was set as 1 for fold-change calculation. (E-G) Primary hepatocytes were infected with either adenoviral vector expressing GPR110 (ADV-GPR110) or control ADV-GFP, followed by transfecting with scramble or shSCD1-1 or shSCD1-2 plasmids for another 72 h. Intracellular lipids were extracted and (E) CHO, (F) TG, and (G) FFA were assessed. STC, standard chow diet; i.v., intravenous injection; s.c., subcutaneous injection; ASO, antisense oligonucleotides. CHO, cholesterol; TG, triglyceride; FFA, free fatty acid. Data represents as mean  $\pm$  SEM; n = 3 per group; repeated with three independent experiments; P value analysed by two-tailed Student's t test. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.



**Figure 7: Inhibition of SCD1 alleviates the glucose impairment in mice with hepatic GPR110 overexpression.** Eight-week-old male C57BL/6J mice were infected with either  $3 \times 10^{11}$  copies of rAAV encoding GPR110 (rAAV-GPR110, i.v.) or control (rAAV-GFP, i.v.) and SCD1 inhibitor (MK8245, 10 mg/kg BW/week, p.o.) or inhibitor vehicle (inhibitor-Veh., p.o.) received HFD feeding. (A) Schematic illustration of viral treatments. (B) Hepatic mRNA expression levels of GPR110 from different groups of mice received rAAV and inhibitor fed with HFD respectively, as determined by qPCR analysis. (C) Left panel: immunoblotting analysis for the hepatic protein expression level of GPR110 and SCD1 from different groups of mice fed with HFD. Right panel: quantification of protein expression levels of GPR110 and SCD1. Protein expression levels were normalized to the expression of  $\beta$ -tubulin. Each lane is a sample from a different individual; n = 3 per group. (D) Body weight and (E) fasting blood glucose level were measured at different weeks upon rAAV and inhibitor injection. (F) The fasting blood insulin level and (G) HOMA-IR index were measured and calculated according to the formula  $[Fasting\ blood\ glucose\ (mmol/L) \times Fasting\ blood\ insulin\ (mIU/L)]/22.5$  for the HFD-fed rAAV-GPR110 or rAAV-GFP mice at the end of the experiment. (H) GTT (1

g/kg BW, left) and AUC (right) of serum glucose at the week of 10. (I) PTT (1 g/kg BW, left) and AUC (right) of serum glucose at week 11. (J) ITT (0.5 U/kg BW, left) and AUC (right) of serum glucose at week of 12. mRNA expression levels of the target genes were normalized to the expression of mouse GAPDH. rAAV-NC group was set as 1 for fold-change calculation. HFD, high-fat diet; i.v., intravenous injection; p.o., oral administration; ASO, antisense oligonucleotides; BW, body weight; GTT, glucose tolerance test; PTT, pyruvate tolerance test; ITT, insulin tolerance test; AUC, area under curve; NC, negative control; HOMA-IR, homeostasis model assessment-estimated insulin resistance. Data represents as mean  $\pm$  SEM; n = 8 mice per group; repeated with three independent experiments; P value analysed by two-tailed Student's t test. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.




**Figure 8: Inhibition of hepatic SCD1 partially alleviates the severity of hepatic steatosis in GPR110**


**overexpression mice.** Eight-week-old male C57BL/6N mice were infected with either  $3 \times 10^{11}$  copies of rAAV encoding GPR110 (rAAV-GPR110, i.v.) or control (rAAV-GFP, i.v.) and administered with SCD1 inhibitor (MK8245, 10 mg/kg BW, p.o.) or inhibitor vehicle (inhibitor-Veh., p.o.) received HFD feeding. (A) Serum CHO, (B) serum TG and (C) serum FFA levels were measured at the end of experiment. (D) Serum HDL and LDL, (E) AST and ALT level of each group of mice were measured at the end of the experiment. (F) The ratio of the liver weight against body weight was calculated after sacrificing the mice from four different groups. (G) Representative gross pictures of liver tissues (upper panels), representative images of H&E (middle panels) and Oil Red O (lower panels) staining of liver sections (200 μm). The percentage of lipid area according to H&E staining (right panel);  $n = 3$  per group. (H) Hepatic CHO, (I) hepatic TG and (J) hepatic FFA were normalized by the weight of liver samples used for lipid extraction. STC, standard chow diet; HFD, high-fat diet; i.v., intravenous injection; p.o., oral administration; CHO, cholesterol; TG,



triglyceride; FFA, free fatty acid; HDL, high-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate transaminase; ALT, alanine transaminase; H&E, hematoxylin-eosin. Data represents as mean  $\pm$  SEM; n = 8 mice per group; repeated with three independent experiments; P value analyzed by two-tailed Student's t test. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.




**Figure 9: Hepatic expression of GPR110 is upregulated in obese patients with hepatic steatosis when compared to those with normal liver morphology, which is positively associated with hepatic SCD1 expression level.** NAFLD patients have higher hepatic expression of GPR110 accompanied with increased mRNA SCD1 expression. (A) Normalized Log<sub>2</sub> mRNA expression of GPR110 in lean people without NAFLD (n = 12), obese people without NAFLD (n = 17) or obese patients with NAFLD (n = 8) according to the GEO database (GEO; Profile # GDS4881 / 8126820). (B) Correlation between GPR110 and SCD1 in liver of human subjects based on the GEO database. (C) Representative images of liver tissues with H&E staining (upper panels) and immunohistochemical staining (IHC) of GPR110 (lower panels) from patients with different degree of NAFLD (200  $\mu$ m). The percentage of GPR110 positive area according to H&E staining (right panel). The percentage of GPR110 positive areas according to IHC staining (right panel); n = 3 per group. Data represents as mean  $\pm$  SEM. P value analyzed by two-tailed Student's t test. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.



**Supplementary Figure 1: Related to Fig. 2. Hepatic overexpression of GPR110 in STC-fed mice exhibits mild metabolic abnormalities.** Eight-week-old male C57BL/6J mice were infected with  $3 \times 10^{11}$  copies of AAV encoding GPR110 (rAAV-GPR110, i.v.) or control (rAAV-GFP, i.v.) and fed with STC diet. (A) Schematic illustration of viral treatments. (B) Hepatic mRNA expression levels of GPR110 from STC-fed mice with liver-specific GPR110 overexpression as determined by qPCR analysis. (C) Left panel: immunoblotting analysis of hepatic protein expression level of GPR110 from STC-fed mice liver with GPR110 overexpression. Right panel: quantification of hepatic protein expression levels of GPR110. Each lane is a sample from a different individual;  $n = 3$  per group. (D) Change of body weight and (E) fasting blood glucose at different weeks upon rAAV injection were measured. (F) Fasting blood insulin level and (G) HOMA-IR values were measured and calculated at the end of the experiment. (H) GTT (1 g/kg BW, left) and area under curve (AUC, right) of serum glucose at the week of 10. (I) PTT (1 g/kg BW, left) and AUC (right) of serum glucose at week 11. (J) ITT (0.5 U/kg BW, left) and AUC (right) of serum glucose at week

12. mRNA expression levels of the target genes were normalized to the expression of mouse GAPDH. STC, standard chow diet; BW, body weight; i.v., intravenous injection; GTT, glucose tolerance test; PTT, pyruvate tolerance test; ITT, insulin tolerance test; AUC, area under curve; NC, negative control; HOMA-IR, homeostasis model assessment-estimated insulin resistance. Data represents as mean  $\pm$  SEM; n = 8 mice per group; repeated with three independent experiments; P value analyzed by two-tailed Student's t test. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.



**Supplementary Figure 2: Related to Figure 3. Hepatic knockdown of GPR110 in STC-fed mice does not exhibit metabolic abnormalities.** Eight-week-old male C57BL/6J mice were infected with two different sequences of GPR110 antisense oligonucleotides (ASO1-GPR110, ASO2-GPR110, 5 mg/kg BW, one dose per week, s.c.) or scrambled control (ASO-NC, s.c.) received STC feeding, respectively. (A) Schematic illustration of viral treatments. (B) mRNA expression levels of GPR110 in liver and kidney as determined by qPCR analysis. mRNA expression levels of GPR110 in different tissues were normalized to the expression of mouse GAPDH. (C) Left panel: immunoblotting analysis of hepatic protein expression level of GPR110 from STC-fed mice liver with GPR110 knockdown. Right panel: quantification of hepatic protein expression levels of GPR110. Each lane is a sample from a different individual; n = 3 per group. (D) Change of body weight and (E) fasting blood glucose at different weeks upon rAAV injection were measured. (F) Fasting blood insulin level and (G) HOMA-IR values were measured and calculated at the end of the experiment. (H) GTT (1 g/kg BW, left) and area under curve (AUC, right) of serum glucose at the week of 10. (I) PTT (1 g/kg BW, left) and AUC (right) of serum glucose at week 11. (J) ITT (0.5 U/kg BW, left) and AUC (right) of serum glucose at week of 12. mRNA expression levels of the target genes were normalized

to the expression of mouse GAPDH. STC, standard chow diet; s.c., subcutaneous injection; ASO, antisense oligonucleotides; BW, body weight; GTT, glucose tolerance test; PTT, pyruvate tolerance test; ITT, insulin tolerance test; AUC, area under curve; NC, negative control; HOMA-IR, homeostasis model assessment-estimated insulin resistance. Data represents as mean  $\pm$  SEM; n = 8 mice per group; repeated with three independent experiments; P value analyzed by two-tailed Student's t test. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.

**Supplementary Table 3: Expression of GPCRs in the liver of mice fed with either STC or HFD diet for 8 weeks by gene expression microarray analysis (Affymetrix Mouse Exon 1.0 ST Array).**

Gene Accession	Gene Symbol	Gene Description	STC		HFD		P value
			average	SD	average	SD	
NM_008308	Htr1a	5-hydroxytryptamine (serotonin) receptor 1A	5.52	0.46	5.67	0.45	0.64018
NM_010482	Htr1b	5-hydroxytryptamine (serotonin) receptor 1B	6.27	0.34	5.97	0.17	0.13440
NM_008309	Htr1d	5-hydroxytryptamine (serotonin) receptor 1D	4.44	0.51	4.14	0.52	0.50166
NM_008310	Htr1f	5-hydroxytryptamine (serotonin) receptor 1F	5.94	0.29	6.03	0.29	0.60580
NM_172812	Htr2a	5-hydroxytryptamine (serotonin) receptor 2A	6.47	0.34	6.74	0.37	0.36038
NM_008311	Htr2b	5-hydroxytryptamine (serotonin) receptor 2B	4.9	0.75	4.86	0.76	0.91875
NM_008312	Htr2c	5-hydroxytryptamine (serotonin) receptor 2C	8.03	0.31	8.22	0.38	0.38376
NM_013561	Htr3a	5-hydroxytryptamine (serotonin) receptor 3A	4.97	0.52	4.86	0.51	0.75293
NM_020274	Htr3b	5-hydroxytryptamine (serotonin) receptor 3B	5.81	0.83	5.75	0.89	0.90944
NM_008314	Htr5a	5-hydroxytryptamine (serotonin) receptor 5A	5.93	0.43	6.05	0.44	0.72994
NM_010483	Htr5b	5-hydroxytryptamine (serotonin) receptor 5B	4.49	0.15	5.28	0.15	0.41513
NM_021358	Htr6	5-hydroxytryptamine (serotonin) receptor 6	5.9	0.39	6.37	0.30	0.24233
NM_008315	Htr7	5-hydroxytryptamine (serotonin) receptor 7	4.63	0.50	4.95	0.46	0.42411
NM_001008533	Adora1	adenosine A1 receptor	7.07	1.04	8.51	0.64	0.00637
NM_009630	Adora2a	adenosine A2a receptor	5.15	0.18	5.44	0.16	0.32188
NM_007413	Adora2b	adenosine A2b receptor	4.74	0.85	5.26	0.61	0.32740
NM_027025	Adora3	adenosine A3 receptor	4.96	0.47	5	0.48	0.90179
NM_009631	Adora3	adenosine A3 receptor	3.94	0.96	4.36	1.07	0.49665
NM_013461	Adra1a	adrenergic receptor, alpha 1a	6.36	0.62	6.99	0.47	0.04982
NM_007416	Adra1b	adrenergic receptor, alpha 1b	8.33	0.62	8.5	0.65	0.66073
NM_013460	Adra1d	adrenergic receptor, alpha 1d	5.94	0.39	6.45	0.31	0.18180
NM_007417	Adra2a	adrenergic receptor, alpha 2a	5.95	0.38	6.12	0.40	0.54876
NM_009633	Adra2b	adrenergic receptor, alpha 2b	8.09	0.63	8.81	0.58	0.03652
NM_007418	Adra2c	adrenergic receptor, alpha 2c	8.02	0.53	8.26	0.43	0.53429

NM_007419	Adrb1	adrenergic receptor, beta 1	6.48	0.45	7.02	0.43	0.34887
NM_007420	Adrb2	adrenergic receptor, beta 2	5.54	0.80	5.84	0.72	0.44498
NM_013462	Adrb3	adrenergic receptor, beta 3	4.02	0.81	4.07	0.88	0.91950
NM_177322	Agtr1a	angiotensin II receptor, type 1a	9.65	0.26	9.74	0.24	0.51518
NM_175086	Agtr1b	angiotensin II receptor, type 1b	5.32	0.32	5.74	0.30	0.05626
NM_011784	Aplnr	apelin receptor	4.98	1.00	5.61	0.31	0.19545
NM_016847	Avpr1a	arginine vasopressin receptor 1A	7.3	0.61	6.76	0.42	0.05483
NM_019404	Avpr2	arginine vasopressin receptor 2	3.37	0.49	4.03	0.64	0.40725
NM_009766	Brs3	bombesin-like receptor 3	6.09	0.47	6.02	0.46	0.83354
NM_007539	Bdkrb1	bradykinin receptor, beta 1	4.99	0.50	5.1	0.58	0.82810
NM_009747	Bdkrb2	bradykinin receptor, beta 2	5.59	0.59	5.83	0.48	0.41334
NM_007726	Cnr1	cannabinoid receptor 1 (brain)	7.86	0.47	7.59	0.44	0.30064
NM_009924	Cnr2	cannabinoid receptor 2 (macrophage)	4.53	0.39	4.46	0.33	0.80140
NM_011798	Xcr1	chemokine (C motif) receptor 1	5.38	0.20	5.46	0.58	0.81747
NM_009912	Ccr1	chemokine (C-C motif) receptor 1	3.69	0.86	2.87	0.84	0.12177
NM_007721	Ccr10	chemokine (C-C motif) receptor 10	4.16	1.08	4.48	1.10	0.65062
NM_009915	Ccr2	chemokine (C-C motif) receptor 2	4.86	0.42	5.48	0.38	0.01481
NM_009914	Ccr3	chemokine (C-C motif) receptor 3	2.85	0.80	3.43	0.83	0.47266
NM_009916	Ccr4	chemokine (C-C motif) receptor 4	0.42	1.66	1.81	1.51	0.11360
NM_009917	Ccr5	chemokine (C-C motif) receptor 5	6.13	0.29	6.38	0.35	0.49865
NM_009835	Ccr6	chemokine (C-C motif) receptor 6	4.71	0.44	5.02	0.46	0.25030
NM_007719	Ccr7	chemokine (C-C motif) receptor 7	4.75	0.41	5.2	0.42	0.39125
NM_001166625	Ccr9	chemokine (C-C motif) receptor 9	5.61	0.11	5.44	0.14	0.14825
NM_145700	Ccr11	chemokine (C-C motif) receptor-like 1	5.49	0.36	5.6	0.37	0.67156
NM_017466	Ccr12	chemokine (C-C motif) receptor-like 2	5.43	0.52	5.19	0.68	0.51424
NM_009987	Cx3cr1	chemokine (C-X3-C) receptor 1	5.26	0.74	5.27	0.76	0.98819
NM_178241	Cxcr1	chemokine (C-X-C motif) receptor 1	5.9	0.88	5.4	0.71	0.23663
NM_009909	Cxcr2	chemokine (C-X-C motif) receptor 2	6.17	0.51	5.91	0.38	0.28316



NM_009910	Cxcr3	chemokine (C-X-C motif) receptor 3	4.19	0.86	3.81	0.86	0.37835
NM_009911	Cxcr4	chemokine (C-X-C motif) receptor 4	5.26	0.30	5.38	0.32	0.49019
NM_030712	Cxcr6	chemokine (C-X-C motif) receptor 6	4.62	0.29	4.37	0.29	0.36634
NM_007722	Cxcr7	chemokine (C-X-C motif) receptor 7	5.11	0.22	5.54	0.21	0.24448
NM_008153	Cmklr1	chemokine-like receptor 1	6.52	0.26	6.59	0.27	0.65239
NM_009827	Cckar	cholecystokinin A receptor	5.15	0.53	5.99	0.25	0.02900
NM_007627	Cckbr	cholecystokinin B receptor	5.27	0.59	5.76	0.48	0.20122
NM_001112697	Chrm1	cholinergic receptor, muscarinic 1, CNS	5.28	0.32	5.79	0.32	0.24786
NM_203491	Chrm2	cholinergic receptor, muscarinic 2, cardiac	3	1.34	3.02	1.49	0.98491
NM_033269	Chrm3	cholinergic receptor, muscarinic 3, cardiac	5.55	0.62	6.44	0.54	0.01491
NM_007699	Chrm4	cholinergic receptor, muscarinic 4	4.07	1.03	4.1	0.96	0.95456
NM_205783	Chrm5	cholinergic receptor, muscarinic 5	4.6	0.43	4.65	0.42	0.92204
NM_007389	Chrna1	cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle)	4.76	0.60	5.1	0.51	0.31847
NM_144803	Chrna2	cholinergic receptor, nicotinic, alpha polypeptide 2 (neuronal)	6.61	0.62	6.89	0.62	0.54576
NM_145129	Chrna3	cholinergic receptor, nicotinic, alpha polypeptide 3	6.22	0.42	6.35	0.39	0.54345
NM_015730	Chrna4	cholinergic receptor, nicotinic, alpha polypeptide 4	5.45	0.46	5.47	0.41	0.95686
NM_176844	Chrna5	cholinergic receptor, nicotinic, alpha polypeptide 5	4.74	0.61	5	0.49	0.45891
NM_021369	Chrna6	cholinergic receptor, nicotinic, alpha polypeptide 6	3.66	1.48	2.93	1.41	0.33627
NM_007390	Chrna7	cholinergic receptor, nicotinic, alpha polypeptide 7	8.97	0.24	9.15	0.32	0.32351
NM_009601	Chrnb1	cholinergic receptor, nicotinic, beta polypeptide 1 (muscle)	7.25	0.35	7.2	0.35	0.86077
NM_009602	Chrnb2	cholinergic receptor, nicotinic, beta polypeptide 2 (neuronal)	4.42	0.60	5.27	0.44	0.21835
NM_173212	Chrnb3	cholinergic receptor, nicotinic, beta polypeptide 3	4.23	0.50	4.4	0.50	0.53936
NM_148944	Chrnb4	cholinergic receptor, nicotinic, beta polypeptide 4	6.09	0.22	6.4	0.21	0.15197
NM_021600	Chrnd	cholinergic receptor, nicotinic, delta polypeptide	5.86	0.52	6.3	0.62	0.30291
NM_009603	Chrne	cholinergic receptor, nicotinic, epsilon polypeptide	5.18	0.26	5.22	0.39	0.90632
NM_009604	Chrng	cholinergic receptor, nicotinic, gamma polypeptide	5.79	0.55	6.04	0.54	0.45388
NM_010169	F2r	coagulation factor II (thrombin) receptor	9.13	0.78	9.12	0.79	0.97725
NM_007974	F2r1	coagulation factor II (thrombin) receptor-like 1	3.73	0.55	4.71	0.38	0.05457

NM_010170	F2rl2	coagulation factor II (thrombin) receptor-like 2	4.81	0.26	5.09	0.25	0.19600
NM_007975	F2rl3	coagulation factor II (thrombin) receptor-like 3	5.77	0.46	5.81	0.46	0.90587
NM_009779	C3ar1	complement component 3a receptor 1	6.59	0.49	7.06	0.52	0.10524
NM_021476	Cysltr1	cysteinyl leukotriene receptor 1	4.78	0.56	5.25	0.73	0.25262
NM_133720	Cysltr2	cysteinyl leukotriene receptor 2	4.5	1.06	3.94	1.06	0.28245
NM_010076	Drd1a	dopamine receptor D1A	4.43	0.40	3.95	0.47	0.17215
NM_010077	Drd2	dopamine receptor D2	8.71	0.32	8.86	0.27	0.38864
NM_007877	Drd3	dopamine receptor D3	5.25	0.77	6.06	0.57	0.09265
NM_007878	Drd4	dopamine receptor D4	8.21	0.47	8.4	0.46	0.55598
NM_010332	Ednra	endothelin receptor type A	7.31	0.53	7.82	0.54	0.08885
NM_007904	Ednrb	endothelin receptor type B	7.72	0.38	8.29	0.43	0.04531
NM_013523	Fshr	follicle stimulating hormone receptor	5.06	0.66	5.41	0.50	0.32926
NM_013521	Fpr1	formyl peptide receptor 1	6.7	0.23	6.88	0.32	0.51783
NM_008039	Fpr2	formyl peptide receptor 2	4.87	0.31	5.04	0.52	0.61891
NM_194057	Ffar1	free fatty acid receptor 1	3.57	0.89	3.78	0.94	0.66838
NM_146187	Ffar2	free fatty acid receptor 2	6.27	0.36	6.52	0.36	0.27399
NM_174985	Gpbar1	G protein-coupled bile acid receptor 1	5.49	0.63	5.11	0.55	0.40075
NM_146250	Gpr1	G protein-coupled receptor 1	4.51	0.13	4.63	0.13	0.54999
NM_178760	Gpr107	G protein-coupled receptor 107	7.34	0.52	7.54	0.54	0.62716
NM_030084	Gpr108	G protein-coupled receptor 108	8.36	0.39	8.12	0.38	0.39528
NM_133776	Gpr110	G protein-coupled receptor 110	7.71	1.96	3.83	0.95	0.00001
NM_001014394	Gpr113	G protein-coupled receptor 113	6.84	0.31	7.36	0.38	0.04368
NM_030067	Gpr115	G protein-coupled receptor 115	4.6	0.30	4.79	0.29	0.67355
NM_181748	Gpr120	G protein-coupled receptor 120	5.58	0.38	5.77	0.38	0.64680
NM_177469	Gpr123	G protein-coupled receptor 123	8.27	0.35	8.33	0.34	0.84204
NM_054044	Gpr124	G protein-coupled receptor 124	5.04	1.40	5.49	1.38	0.53999
NM_001002268	Gpr126	G protein-coupled receptor 126	4.97	0.87	5.2	0.94	0.63814
NM_172825	Gpr128	G protein-coupled receptor 128	5.7	0.58	5.54	0.59	0.73760

NM_019925	Gpr132	G protein-coupled receptor 132	4.76	0.36	4.8	0.39	0.88371
NM_181752	Gpr135	G protein-coupled receptor 135	6	0.23	6.25	0.21	0.07325
NM_207220	Gpr137	G protein-coupled receptor 137	6.71	0.55	6.82	0.55	0.77283
NR_003568	Gpr137b-ps	G protein-coupled receptor 137B, pseudogene	6.07	0.48	6.55	0.55	0.20238
NM_027518	Gpr137c	G protein-coupled receptor 137C	7.3	0.53	7.51	0.51	0.42757
NM_181754	Gpr141	G protein-coupled receptor 141	3.35	1.47	2.73	1.36	0.38175
NM_181749	Gpr142	G protein-coupled receptor 142	4.28	0.54	4.23	0.57	0.92814
NM_010951	Gpr143	G protein-coupled receptor 143	7.46	0.55	7.76	0.48	0.24913
NM_001038703	Gpr146	G protein-coupled receptor 146	9.92	0.35	9.62	0.32	0.10740
NM_177346	Gpr149	G protein-coupled receptor 149	2.46	1.77	3.15	1.42	0.46170
NM_175495	Gpr150	G protein-coupled receptor 150	3.6	1.77	4.59	0.50	0.23267
NM_181543	Gpr151	G protein-coupled receptor 151	6.17	0.33	6.45	0.42	0.38221
NM_206973	Gpr152	G protein-coupled receptor 152	5.48	0.55	5.14	0.43	0.24115
NM_178406	Gpr153	G protein-coupled receptor 153	7.72	0.36	7.88	0.33	0.54607
NM_153394	Gpr156	G protein-coupled receptor 156	6	0.43	6.24	0.42	0.40792
NM_177366	Gpr157	G protein-coupled receptor 157	7.22	0.20	7.47	0.21	0.15631
NM_001004761	Gpr158	G protein-coupled receptor 158	5.97	0.45	6.21	0.45	0.38980
NM_013533	Gpr162	G protein-coupled receptor 162	4.12	1.30	4.31	1.29	0.79321
NM_001025381	Gpr17	G protein-coupled receptor 17	5.71	0.39	5.7	0.37	0.97438
NM_173398	Gpr171	G protein-coupled receptor 171	3.74	1.83	3.7	1.69	0.95894
NM_029643	Gpr172b	G protein-coupled receptor 172B	6.6	0.61	6.53	0.63	0.87711
NM_201367	Gpr176	G protein-coupled receptor 176	4.09	0.62	4.63	0.61	0.23916
NM_182806	Gpr18	G protein-coupled receptor 18	3.55	1.46	3.27	1.48	0.69476
NM_021434	Gpr180	G protein-coupled receptor 180	8.69	0.32	8.64	0.31	0.79329
NM_007412	Gpr182	G protein-coupled receptor 182	8.48	0.41	8.7	0.41	0.31468
NM_183031	Gpr183	G protein-coupled receptor 183	6.61	0.37	6.46	0.32	0.56357
NM_001167693	Gpr19	G protein-coupled receptor 19	5.28	0.60	5.53	0.58	0.60395
NM_173365	Gpr20	G protein-coupled receptor 20	5.38	0.48	5.47	0.44	0.74193

NM_177383	Gpr21	G protein-coupled receptor 21	3.29	1.00	3.68	1.05	0.59572
NM_175191	Gpr22	G protein-coupled receptor 22	4.87	0.40	4.55	0.33	0.14974
NM_173410	Gpr26	G protein-coupled receptor 26	7.08	0.28	7.07	0.28	0.94997
NM_008158	Gpr27	G protein-coupled receptor 27	6.94	0.37	6.96	0.34	0.92842
NM_029771	Gpr30	G protein-coupled receptor 30	5.81	0.40	5.95	0.27	0.60764
NM_008159	Gpr33	G protein-coupled receptor 33	4.37	0.24	4.15	0.22	0.15585
NM_011823	Gpr34	G protein-coupled receptor 34	3.41	0.79	3.48	0.75	0.86326
NM_022320	Gpr35	G protein-coupled receptor 35	5.49	0.40	5.94	0.42	0.17594
NM_010338	Gpr37	G protein-coupled receptor 37	5.57	0.40	5.97	0.36	0.25086
NM_134438	Gpr3711	G protein-coupled receptor 37-like 1	5.08	0.44	5.51	0.46	0.23055
NM_027677	Gpr39	G protein-coupled receptor 39	6.73	0.59	6.76	0.59	0.94250
NM_175668	Gpr4	G protein-coupled receptor 4	4.67	0.45	4.9	0.41	0.42856
NM_009962	Gpr44	G protein-coupled receptor 44	5.87	0.36	6.12	0.27	0.45746
NM_053107	Gpr45	G protein-coupled receptor 45	4.35	0.65	4.51	0.68	0.75453
NM_018882	Gpr56	G protein-coupled receptor 56	6.58	0.32	6.78	0.32	0.60614
NM_199058	Gpr6	G protein-coupled receptor 6	4.25	0.81	4.21	0.84	0.92822
NM_175470	Gpr61	G protein-coupled receptor 61	5.61	0.37	5.77	0.41	0.60697
NM_030733	Gpr63	G protein-coupled receptor 63	4.55	0.35	4.59	0.34	0.91106
NM_178712	Gpr64	G protein-coupled receptor 64	4.3	1.20	5.69	1.16	0.08922
NM_175493	Gpr68	G protein-coupled receptor 68	6.16	0.34	6.16	0.34	0.99817
NM_175490	Gpr75	G protein-coupled receptor 75	5.49	0.36	5.51	0.41	0.94538
NM_176912	Gpr77	G protein-coupled receptor 77	5.67	0.35	6.11	0.36	0.08388
NM_175520	Gpr81	G protein-coupled receptor 81	4.93	0.49	5.53	0.28	0.16911
NM_175669	Gpr82	G protein-coupled receptor 82	3.63	0.44	3.45	0.39	0.66910
NM_010287	Gpr83	G protein-coupled receptor 83	4.2	0.34	4.88	0.42	0.05833
NM_030720	Gpr84	G protein-coupled receptor 84	3.52	0.29	4.6	0.33	0.16888
NM_145066	Gpr85	G protein-coupled receptor 85	7.46	0.40	7.63	0.39	0.57426
NM_032399	Gpr87	G protein-coupled receptor 87	5.91	0.82	5.85	0.81	0.91283

NM_026229	Gpr89	G protein-coupled receptor 89	8.38	0.49	8.29	0.46	0.76141
NM_173036	Gpr97	G protein-coupled receptor 97	6.14	0.37	6.59	0.19	0.10953
NM_054053	Gpr98	G protein-coupled receptor 98	6.17	0.67	6.97	0.47	0.01870
NM_181444	Gprc5a	G protein-coupled receptor, family C, group 5, member A	3.95	0.73	4.03	0.71	0.88108
NM_022420	Gprc5b	G protein-coupled receptor, family C, group 5, member B	2.5	1.86	4.5	1.85	0.06886
NM_001110337	Gprc5c	G protein-coupled receptor, family C, group 5, member C	8.5	0.33	8.47	0.38	0.90230
NM_147217	Gprc5c	G protein-coupled receptor, family C, group 5, member C	7.78	0.46	7.85	0.52	0.82192
NM_053118	Gprc5d	G protein-coupled receptor, family C, group 5, member D	3.23	1.15	3.31	1.19	0.92889
NM_153071	Gprc6a	G protein-coupled receptor, family C, group 6, member A	5.06	0.75	5.78	0.48	0.14073
NM_010254	Galr2	galanin receptor 2	5.66	0.28	5.62	0.29	0.86159
NM_015738	Galr3	galanin receptor 3	5.92	0.35	6.28	0.24	0.36657
NM_008177	Grpr	gastrin releasing peptide receptor	2.85	0.56	3.89	0.60	0.12143
NM_010323	Gnrhr	gonadotropin releasing hormone receptor	4.36	0.43	4.47	0.32	0.74652
NM_177330	Ghsr	growth hormone secretagogue receptor	6.31	0.30	6.41	0.31	0.59179
NM_008285	Hrh1	histamine receptor H1	4.98	0.34	5.21	0.31	0.19105
NM_001010973	Hrh2	histamine receptor H2	4.18	0.92	2.91	0.78	0.00692
NM_133849	Hrh3	histamine receptor H3	7.97	0.44	8.14	0.38	0.46158
NM_153087	Hrh4	histamine receptor H4	4	0.48	3.77	0.47	0.41377
NM_001163027	Hctr1	hypocretin (orexin) receptor 1	5.15	0.63	5.79	0.47	0.16738
NM_198962	Hctr2	hypocretin (orexin) receptor 2	5.43	0.94	5.13	0.91	0.51489
NM_053244	Kiss1r	KISS1 receptor	6.12	0.82	6.81	0.66	0.23507
NM_010195	Lgr5	leucine rich repeat containing G protein coupled receptor 5	7.03	0.60	7.78	0.59	0.10732
NM_008519	Ltb4r1	leukotriene B4 receptor 1	5.94	0.16	5.91	0.15	0.89357
NM_020490	Ltb4r2	leukotriene B4 receptor 2	6.56	0.44	6.8	0.33	0.31610
NM_013582	Lhcgr	luteinizing hormone/choriogonadotropin receptor	5.56	0.51	5.33	0.51	0.49212
NM_010336	Lpar1	lysophosphatidic acid receptor 1	6.56	0.34	6.81	0.33	0.33956
NM_020028	Lpar2	lysophosphatidic acid receptor 2	5.55	0.35	6.11	0.20	0.12832
NM_022983	Lpar3	lysophosphatidic acid receptor 3	8.52	0.31	8.81	0.30	0.12775

NM_175271	Lpar4	lysophosphatidic acid receptor 4	4.49	0.37	4.46	0.35	0.89175
NM_175116	Lpar6	lysophosphatidic acid receptor 6	8.99	0.31	9.36	0.32	0.17935
NM_008552	Mas1	MAS1 oncogene	4.67	0.72	5.25	0.73	0.17770
NM_203490	Mrgprd	MAS-related GPR, member D	4.74	0.48	5.3	0.29	0.10883
NM_175534	Mrgpre	MAS-related GPR, member E	6.22	0.38	6.39	0.37	0.40279
NM_145379	Mrgprf	MAS-related GPR, member F	6.13	0.99	6.46	1.02	0.60085
NM_203492	Mrgprg	MAS-related GPR, member G	5.52	0.36	5.42	0.35	0.66871
NM_207540	Mrgprx1	MAS-related GPR, member X1	3.19	0.16	2.4	0.17	0.02077
NM_145132	Mchr1	melanin-concentrating hormone receptor 1	3.26	1.32	3.01	1.41	0.75052
NM_008559	Mc1r	melanocortin 1 receptor	4.62	0.29	4.7	0.32	0.78990
NM_008560	Mc2r	melanocortin 2 receptor	4.41	0.29	4.65	0.36	0.26810
NM_008561	Mc3r	melanocortin 3 receptor	3.77	0.35	3.77	0.43	0.99588
NM_016977	Mc4r	melanocortin 4 receptor	5.09	0.58	5.17	0.51	0.82331
NM_013596	Mc5r	melanocortin 5 receptor	5.1	0.19	5.06	0.18	0.89032
NM_008639	Mtnr1a	melatonin receptor 1A	6.25	0.56	7.62	0.53	0.01514
NM_145712	Mtnr1b	melatonin receptor 1B	4.49	1.11	3.95	1.17	0.34537
NM_008703	Nmbr	neuromedin B receptor	4.8	0.25	5.09	0.27	0.09007
NM_010341	Nmur1	neuromedin U receptor 1	4.19	0.94	3.05	1.05	0.06309
NM_153079	Nmur2	neuromedin U receptor 2	4.51	0.55	4.35	0.59	0.65706
NM_133192	Npffr2	neuropeptide FF receptor 2	5.76	0.36	5.46	0.40	0.33905
NM_175678	Npsr1	neuropeptide S receptor 1	5.25	0.53	5.7	0.52	0.31063
NM_010934	Npy1r	neuropeptide Y receptor Y1	4	0.54	4.57	0.50	0.05136
NM_008731	Npy2r	neuropeptide Y receptor Y2	3.85	0.73	4.41	0.75	0.53172
NM_016708	Npy5r	neuropeptide Y receptor Y5	4.6	0.41	4.34	0.29	0.30368
NM_010935	Npy6r	neuropeptide Y receptor Y6	3.02	0.43	3.47	0.34	0.22168
NM_018766	Ntsr1	neurotensin receptor 1	6.92	0.51	7.03	0.50	0.79865
NM_008747	Ntsr2	neurotensin receptor 2	8.69	0.25	8.95	0.27	0.30427
NM_013622	Oprd1	opioid receptor, delta 1	6.91	0.43	7.03	0.38	0.67278

NM_011011	Oprk1	opioid receptor, kappa 1	3.78	0.57	3.79	0.54	0.97964
NM_001039652	Oprm1	opioid receptor, mu 1	5.98	0.47	6.13	0.46	0.67908
NM_011012	Oprl1	opioid receptor-like 1	5	0.19	5.31	0.18	0.20871
NM_008106	Opn1mw	opsin 1 (cone pigments), medium-wave-sensitive (color blindness, deutan)	3.76	0.90	3.93	0.95	0.84814
NM_007538	Opn1sw	opsin 1 (cone pigments), short-wave-sensitive (color blindness, tritan)	5.52	0.57	5.65	0.59	0.73438
NM_010098	Opn3	opsin 3	5.89	0.40	5.16	0.26	0.00411
NM_001128599	Opn4	opsin 4 (melanopsin)	6.81	0.41	7.19	0.34	0.24053
NM_181753	Opn5	opsin 5	4.88	0.45	5.34	0.44	0.14551
NM_001001490	Oxgr1	oxoglutarate (alpha-ketoglutarate) receptor 1	3.32	0.35	3.51	0.38	0.59082
NM_001081147	Oxtr	oxytocin receptor	4.99	0.87	5.26	0.58	0.54141
NM_021381	Prokr1	prokineticin receptor 1	3.67	0.48	4.18	0.43	0.50837
NM_144944	Prokr2	prokineticin receptor 2	6.45	0.29	6.41	0.28	0.83847
NM_201615	Prhr	prolactin releasing hormone receptor	3.58	0.37	3.45	0.37	0.62331
NM_008962	Ptgdrr	prostaglandin D receptor	4.02	0.51	3.72	0.59	0.34160
NM_013641	Ptger1	prostaglandin E receptor 1 (subtype EP1)	4.66	0.56	4.5	0.47	0.63530
NM_008964	Ptger2	prostaglandin E receptor 2 (subtype EP2)	4.65	0.26	5.29	0.16	0.03072
NM_011196	Ptger3	prostaglandin E receptor 3 (subtype EP3)	3.92	0.42	4.95	0.37	0.23612
NM_001136079	Ptger4	prostaglandin E receptor 4 (subtype EP4)	4.74	0.30	5.22	0.29	0.22462
NM_008966	Ptgrfr	prostaglandin F receptor	3.87	0.55	4.76	0.39	0.03679
NM_008967	Ptgir	prostaglandin I receptor (IP)	5.29	0.52	5.24	0.51	0.86514
NM_008772	P2ry1	purinergic receptor P2Y, G-protein coupled 1	8.36	0.43	8.83	0.33	0.10199
NM_172435	P2ry10	purinergic receptor P2Y, G-protein coupled 10	2.57	0.85	3.44	0.83	0.15845
NM_027571	P2ry12	purinergic receptor P2Y, G-protein coupled 12	6.34	0.18	6.59	0.28	0.34222
NM_028808	P2ry13	purinergic receptor P2Y, G-protein coupled 13	6.68	0.21	6.74	0.29	0.71166
NM_008773	P2ry2	purinergic receptor P2Y, G-protein coupled 2	8.83	0.59	8.79	0.62	0.91505
NM_133200	P2ry14	purinergic receptor P2Y, G-protein coupled, 14	6.01	0.56	6.68	0.68	0.10995
NM_198192	Qrfpr	pyroglutamylated RFamide peptide receptor	6.62	0.37	6.14	0.30	0.00943
NM_178717	Rxfp3	relaxin family peptide receptor 3	4.08	1.52	3.16	1.68	0.27344

NM_181817	Rxfp4	relaxin family peptide receptor 4	3.54	0.90	4.81	0.50	0.01682
NM_212452	Rxfp1	relaxin/insulin-like family peptide receptor 1	5.26	0.49	5.38	0.51	0.76588
NM_080468	Rxfp2	relaxin/insulin-like family peptide receptor 2	5.73	0.47	5.2	0.38	0.05139
NM_009216	Sstr1	somatostatin receptor 1	7.41	0.39	7.6	0.32	0.54433
NM_009218	Sstr3	somatostatin receptor 3	6.56	0.11	6.56	0.12	0.99291
NM_009219	Sstr4	somatostatin receptor 4	7.12	0.32	7.06	0.34	0.76321
NM_007901	S1pr1	sphingosine-1-phosphate receptor 1	8.84	0.34	9.4	0.33	0.05902
NM_010333	S1pr2	sphingosine-1-phosphate receptor 2	5.59	0.63	5.81	0.62	0.60675
NM_010101	S1pr3	sphingosine-1-phosphate receptor 3	6.02	0.44	6.31	0.49	0.41398
NM_010102	S1pr4	sphingosine-1-phosphate receptor 4	4.57	0.65	4.28	0.70	0.44313
NM_053190	S1pr5	sphingosine-1-phosphate receptor 5	6.7	0.31	6.82	0.49	0.72330
NM_032400	Sucnr1	succinate receptor 1	8.82	0.25	9.39	0.29	0.09572
NM_009313	Tacr1	tachykinin receptor 1	4.95	0.51	5.81	0.26	0.15301
NM_009314	Tacr2	tachykinin receptor 2	5.59	0.68	5.74	0.66	0.77054
NM_021382	Tacr3	tachykinin receptor 3	4.82	0.24	5.49	0.23	0.26982
NM_009325	Tbxa2r	thromboxane A2 receptor	4.57	0.80	5.83	0.60	0.23528
NM_011648	Tshr	thyroid stimulating hormone receptor	5.12	0.44	5.44	0.47	0.23447
NM_013696	Trhr	thyrotropin releasing hormone receptor	4.94	0.46	4.66	0.38	0.32957
NM_133202	Trhr2	thyrotropin releasing hormone receptor 2	5.39	0.53	5.39	0.52	0.99232
NM_053205	Taar1	trace amine-associated receptor 1	4.86	0.25	5.15	0.25	0.23825
NM_001007266	Taar2	trace amine-associated receptor 2	1.76	0.85	2.3	0.88	0.36888
NM_001008429	Taar3	trace amine-associated receptor 3	3.39	0.65	3.37	0.64	0.96888
NM_001008499	Taar4	trace amine-associated receptor 4	4.17	0.38	4.49	0.37	0.31870
NM_001009574	Taar5	trace amine-associated receptor 5	5.19	0.21	5.47	0.07	0.12264
NM_001010828	Taar6	trace amine-associated receptor 6	7.27	0.38	7.37	0.37	0.69455
NM_001010829	Taar7a	trace amine-associated receptor 7A	0.71	0.94	1.03	1.00	0.56784
NM_001010827 // NM_001010827	Taar7b // Taar7b	trace amine-associated receptor 7B // trace amine-associated receptor 7B	5.6	0.63	6.36	0.62	0.19868
NM_001010838	Taar7d	trace amine-associated receptor 7D	2.06	1.01	2.52	0.85	0.52164



NM_001010835	Taar7e	trace amine-associated receptor 7E	1.43	1.40	1.24	1.34	0.84692
NM_001010839	Taar7f	trace amine-associated receptor 7F	1.97	1.12	1.92	1.40	0.94460
NM_001010837	Taar8b	trace amine-associated receptor 8B	0.42	0.68	1.16	0.62	0.10033
NM_001010831	Taar9	trace amine-associated receptor 9	4.58	0.23	4.7	0.22	0.46412
NM_145440	Uts2r	urotensin 2 receptor	6.85	0.56	6.9	0.56	0.90845

**Supplementary Table 4: Baseline characteristics of study cohorts.**

NAFLD stage	Mild	Moderate	Severe
<b>Age</b>	49.00 ± 15.10	47.33 ± 15.89	25.67 ± 5.66
<b>Gender (Female/Male)</b>	2/1	0/3	2/1
<b>Body Weight (kg)</b>	66.67 ± 14.41	65.90 ± 15.79	79.00 ± 1.41
<b>Body Height (m)</b>	1.60 ± 0.13	1.70 ± 0.10	1.68 ± 0.01
<b>BMI (kg/m<sup>2</sup>)</b>	25.65 ± 2.06	22.59 ± 3.84	28.08 ± 0.27
<b>Fasting Glucose (mmol/L)</b>	5.07 ± 0.35	6.42 ± 1.42	5.51 ± 1.48
<b>SBP (mmHg)</b>	122.33 ± 11.24	114.33 ± 26.50	130.67 ± 0.71
<b>DPB (mmHg)</b>	76.33 ± 17.04	75.33 ± 17.01	94.00 ± 25.46
<b>Total Cholesterol (mmol/L)</b>	4.29 ± 0.90	3.32 ± 0.52	3.93 ± 1.18
<b>Triglycerides (mmol/L)</b>	1.29 ± 0.47	1.99 ± 1.44	1.06 ± 0.26
<b>HDL (mmol/L)</b>	1.38 ± 0.23 <sup>a</sup>	0.82 ± 0.25	1.05 ± 0.14
<b>LDL (mmol/L)</b>	2.39 ± 0.68	1.82 ± 0.21	2.51 ± 1.28
<b>ALT (U/L)</b>	38.33 ± 27.39	87.33 ± 41.53	91.33 ± 52.33
<b>AST (U/L)</b>	16.33 ± 6.81 <sup>a,b</sup>	46.00 ± 16.00	51.33 ± 16.26
<b>AST/ALT</b>	0.63 ± 0.40	0.63 ± 0.40	0.60 ± 0.21
<b>γGGT (U/L)</b>	117.67 ± 163.10	47.67 ± 6.43	100.67 ± 32.53

Abbreviations: BMI, body mass index; HOMA-IR, homeostasis model assessment of insulin resistance; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high density lipoproteins; LDL, low density lipoproteins; ALT, alanine aminotransferase; AST, aspartate transaminase; γGGT, γ-glutamyl transpeptidase. Data represent as mean ± SEM; a, significant difference between mild and moderate; b, significant difference between mild and severe, no significant differences among the rest groups. P < 0.05 is considered significant.

It is made available under a [CC-BY 4.0 International license](#).